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Carcinogenesis is commonly referred to as a multi-step process in which normal 
cells develop progressively into hyperplasia, carcinoma in situ, invasive cancer and 
metastasis. Several evidences indicate that transcription factors, which act as master 
regulators of embryonic development, may play a central role in this pathologic 
process. Indeed, growing evidence suggests that cancer cells often reactivate latent 
developmental programs in order to efficiently execute the multi-step process of 
tumorigenesis. Reminiscent of their function during development, embryonic 
transcription factors regulate changes in gene expression that promote tumor cell 
growth, cell survival and motility, as well as a morphogenetic process called epithelial-
mesenchymal transition (EMT), which is implicated in both metastasis and tumor 
recurrence. Because of their pivotal roles in tumor progression, these factors represent 
valuable new biomarkers for cancer detection as well as promising new targets for 
alternative anti-cancer therapies. 
 
The present doctoral work explores the role of embryonic transcription factors 
deregulation in epithelial cancers and their therapeutic implications in the frontiers of 
precision oncology. More specifically, the first project identified MDM2 as a specific 
synthetic lethal partner of GATA3, an embryonic master regulator of the mammary 
gland often mutated in estrogen receptor-positive breast cancers. The second project 
identified the homeobox transcription factor HOXA13 as a novel oncogene, whose 
overexpression results in hepatocarcinogenesis in mice through the induction of 
chromosomal instability.  
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By definition, cancer is a class of diseases in which a group of cells undergo 
uncontrolled cell divisions, invasion of adjacent tissues and sometimes spread to other 
locations in the body via lymph or blood1. At first glance, embryonic development and 
cancer seem to have little to do with each other, with the hallmark of the first being the 
tendency for well-organized structures and the second being characterized by 
dysregulation and disorder. However, a lot of research from the past decades has 
shown significant similarities between developmental and cancer biology: for instance, 
embryos undergo rapid growth involving cell migration and cell-cell interactions, which 
are features also seen in the context of cancer. Developmental biologists have 
considered cancer as a special phenomenon that is a product of natural selection with 
respect to cancer cells, although the result of this selection is unfavorable for human 
health and normal development. In fact, the characterization of the molecular biology 
of in-utero development and cancer has revealed that embryogenesis and 
tumorigenesis share common features in terms of biological behaviors such as cell 
migration and invasion2, gene expression and protein profiles3, signaling pathways3,4,5, 
cell differentiation6, the mechanism of immune escape7, among others. Observations 
that genes intricately involved in embryogenesis are also differentially expressed in 
malignancy have led to the idea that ‘oncology recapitulates ontogeny’ (Figure 1).  






FIGURE 1. “Oncology recapitulates ontology”. Similarities and differences between stem 
cells and cancer cells. Created with Biorender.com. 
 
Processes that underlie normal differentiation are often altered during the initiation 
and/or progression of epithelial cancers8,9, which account for roughly 90% of all 
cancers. Epithelia are continuous sheets of tightly linked cells that constitute the 
surfaces and linings of the body. Epithelium provides a protective envelope against 
the external environment and regulates water and nutrient absorption as well as 
glandular secretions. The high cell division rate of epithelia at least partially explains 
why common adult-onset cancers occur in those tissues. In fact, the vast majority of 
epithelia constantly replace damaged or dead cells throughout life. This process of 
continual cell replacement is called tissue homeostasis and is critical for the 
maintenance of adult tissues. The homeostatic replacement of cells varies 
substantially between epithelia. For instance, in the mammary gland, it proceeds 
through cycles of growth and degeneration during and following pregnancy10. Most 
epithelia are also able to repair their tissues and typically wound-induced tissue 
regeneration involves recruitment of epithelial stem cells to replace the damaged cells. 





The adult liver offers an unusual example of this capacity: although its epithelial cells 
do not turn over significantly under physiological conditions, they have an impressive 
capacity to regenerate tissue after injury and, contrary to other tissues, liver repair 
appears to occur without obvious participation of multipotent stem cells but rather 
through proliferation of a  specific sub-population of hepatocytes11,12. 
Aggressive epithelial cancers are enriched for a transcriptional signature shared 
by epithelial adult stem cells13,14 and certain epithelial cancers are known to revert to 
a molecular state reminiscent of their tissue stem cells as they become more 
aggressive15,16,17,18. Molecular profiling of stem and cancer cells has shown that the 
pluripotency of embryonic stem cells (ESCs) and cancer stem cells (CSCs) is at least 
partially regulated by the same well-characterized gene transcriptional circuitry19. This 
circuitry is assembled by specific transcription factors, signal-transducing molecules, 
and epigenetic regulators. A better understanding of this stem-like transcription 
machinery will provide a common conceptual and research framework for basic and 









4. Research project 1: GATA3/MDM2 are synthetic lethal partners in 
estrogen receptor-positive breast cancers and GATA3 expression 
predicts response to nutlin inhibitors 
4.1. Introduction 
4.1.1. Epidemiology of Breast Cancer  
Breast carcinoma is the most prevalent malignancy and the leading cause of 
cancer death in women20.  Together with colon and lung, it is one of the three most 
common cancers worldwide, accounting for the 24,2% of all new cancer cases and 
15% of cancer-related deaths among the female population20 (Figure 4.1.1., source: 
GLOBOCAN 2018). According to the global cancer project (GLOBOCAN) statistics, 
2.1 million women were newly diagnosed with breast cancer in 2018 and more than 




FIGURE 4.1. Pie charts present the distribution of incidence and deaths for the 10 most 
common cancers in 2018 for (A) both sexes and (B) only females. The area of the pie charts 
reflects the proportion of the total number of cases or deaths; non-melanoma skin cancers are 
included in the “other” category. (C) Bar chart of region-specific incidence and mortality age-
standardized rates for cancers of the female breast in 2018. Rates are shown in descending 
order of the world (W) age-standardized rate, and the highest national age-standardized rates 
for incidence and mortality are superimposed. Source: GLOBOCAN 2018. 







TABLE 1.  
New cases and deaths for the top 15 most common cancers worldwide. 
 
With one in eight to ten women diagnosed during their lifetime, breast cancer is 
considered a global health emergency. Nevertheless, it is important to underline that 
both incidence and mortality rates from breast cancer highly differ between countries 
(Figure 4.1.1.C, source GLOBOCAN 2018). For instance, mortality from breast cancer 
is decreasing in developed countries, such as North America and European Union, 
mostly resulting from extensive prevention programs and the use of efficient systemic 
therapies. On the other hand, in developing countries, breast cancer rates have been 
increasing. In particular, South America, Africa, and Asia have seen increases in both 





incidence and mortality rates. The increasing incidence may be partially explained by 
the recent initiation of screening programs while the higher mortality rates likely result 
from a lack of access to the state-of-art diagnostic and therapeutics tools22.  In fact, 
early detection of the disease plays an essential role in reducing the mortality rate and 
improving prognosis23. However, even in the developed countries, only 50% of women 
can benefit diagnostic screening with lower screening rates for immigrant women and 
women with lower income. It is then easy to understand why living in less privileged 
areas is associated with patients’ decreased survival and why timely diagnosis is 
associated with the socio-economic status of women24,25. 
4.1.2. Risk Factors 
Risk factors for the development of breast cancer can be schematically divided 
into hereditary and non-hereditary risk factors. Hereditary or genetic factors include 
inherited mutations in well-known susceptibility genes such as BRCA1 and BRCA226–
28 and family history of breast and ovarian cancers. PALB2 is a BRCA2-interacting 
protein that is crucial for BRCA2 genome caretaker functions29,30 and also interacts 
with BRCA131. Loss-of-function mutations in PALB2 are also associated with an 
increased risk of breast cancer32–34.  
However, genetic factors account for only 5 to 10% of all breast cancer cases, 
with non-hereditary risk factors as major contributors to the uneven incidence 
distribution of the disease worldwide21. This has been shown in studies on migrants: 
when comparing the incidence of breast cancer in low-risk populations migrating to 
high-risk populations areas, it has been revealed that incidence rises in successive 
generations35. Of note, breast cancer incidence is higher in developed countries due 
to the presence of known risk factors associated with better socio-economic status 
and higher gender equality. Among such factors, some are directly related to 
reproduction and exogenous hormone intake (late age at first birth, fewer children, the 
use of oral contraceptive and hormone replacement therapy), while others are related 
to nutrition (alcohol consumption, obesity after menopause, body fat distribution). By 
contrast, breastfeeding and physical activity are known as protective factors36,37. 





4.1.3. Classification  
Breast cancer is a very heterogeneous disease encompassing several entities, all 
having different histology, risk factors, prognosis and clinical response to treatment38. 
In fact, there are up to 21 distinct histological subtypes and at least four different 
molecular subtypes39. Breast cancer classification is therefore challenging. In the past 
years, several parameters have been assessed for classification. These include cell 
of origin, histology, level of invasion and grade, expression of surface molecules and 
gene expression.  
 
According to the level of invasion, breast cancer is classified as carcinoma in situ 
(CIS) or invasive breast cancer (IBC)40.  CIS refers to an abnormal increase in the 
growth of the breast epithelium where the cells still reside in their normal place in the 
ducts and lobules (Figure 4.2.)41. There are two main types of carcinoma in situ: ductal 
carcinoma in situ (DCIS), arising from the cells that line the breast ducts and 
accounting for 83% of in situ cases, and lobular carcinoma in situ (LCIS)  referring to 
an abnormal growth of cells within the breast lobules and accounting for 13% of the 
cases. Other in situ breast cancers have characteristics of both ductal and lobular 
carcinomas or have unknown origins.   
DCIS is considered to be the immediate precursor of invasive breast cancer, but 
it does not necessarily develop into invasive carcinoma (Figure 4.2.). On the contrary, 
LCIS is not considered to be a precursor but only represents a risk factor for the 
development of the invasive breast carcinoma41. 






FIGURE 4.2. The female human breast is composed of thousands of grape-like clusters of 
small glands that produce milk, referred to as terminal duct lobular units (TDLUs). The milk is 
propagated outward through a series of interconnecting and increasingly large ducts that exit 
the nipple. Ductal carcinoma in situ (DCIS) refers to breast epithelial cells that have become 
“cancerous” but still reside in their normal place. (Histological images were obtained and 
adapted from the Digital Atlas of Breast Pathology by Meenakshi Singh, MD ©) Created with 
Biorender.com. 
 
Unfortunately, the vast majority (80%) of breast cancers are invasive or infiltrating, 
which means that the breast epithelial cells have grown outside the walls of glands 
and ducts and invaded the surrounding breast tissue. Invasive breast carcinomas are 
clinically sub-classified into different types based on tumor morphological 
characteristics. Those types include infiltrating ductal carcinoma of no special type and 
a large number of “special types” such as tubular, medullary, mucinous, infiltrating 
lobular and adenoid cystic carcinoma. Features of histological grades such as cellular 





differentiation, nuclear pleomorphism and mitotic count further help pathologists sub-
classify breast tumors42.  
 
Breast cancer is also routinely classified based on the expression of specific 
molecular markers. In particular, clinical decisions are normally made based on the 
expression levels of hormone receptors (estrogen receptor (ER) and progesterone 
receptor (PR)) and Erb-B2 receptor tyrosine kinase 2 (HER2) gene amplification. The 
American Society of Clinical Oncology (ASCO) and the College of American 
Pathologists (CAP) have defined the guidelines for assessing ER and PR (by 
immunohistochemistry (IHC) as well as HER2 (by IHC and fluorescence in situ 
hybridization (FISH)), which dictate the use of endocrine and HER2-targeted therapy 
in breast cancer patients43–46. Based on these three markers, IBCs can be classified 
into the following four molecular categories: luminal A, luminal B, HER2 enriched and 
triple-negative (TNBC) or basal-like breast cancers39,47. The St. Gallen International 
Expert Consensus on the Primary Therapy of Early Breast Cancer additionally defined 
a surrogate to distinguish these four molecular categories based on a combination of 
ER, PR, Ki67% and HER2 IHC status, without a requirement for molecular 
diagnostics48. 
Luminal A subtype accounts for 71% of IBCs and is characterized by the presence 
of hormone receptors (HR; namely ER+ and/or PR+) and the absence of HER2 
amplification. These cancers are characterized by a better prognosis, their slow 
growth, and less aggressiveness compared to the other subtypes and, in particular, 
are responsive to anti-hormone therapy49,50. The Luminal B subtype accounts for 12% 
of IBCs, is also positive for hormone receptors and is further characterized by a high 
positivity for Ki67 (a marker of actively dividing cells for which the cut off is set at 20% 
of positive cells)48 and HER2. Luminal B cancers are of higher grade and are 
associated with a poorer prognosis compared to Luminal A subtypes50. HER2-
enriched breast cancers are characterized by the absence of hormone receptors and 
the presence of HER2 gene amplification (HR-/HER2+). This type of tumor is more 
aggressive and tend to grow faster compared to the HR-positive breast cancers50. 
However, the development of HER2-targeting monoclonal antibodies such as 
trastuzumab51,52 and pertuzumab51,52 and small molecules inhibitors such as 





lapatinib53–55 has substantially improved the management of the disease and the 
outcome of the patients53,56,57. HER2 targeted therapy is now used as a standard of 
care in both early (EBC) and advanced (ABC) breast cancer making HER2-enriched 
breast cancers the one that has seen the most tremendous progress in terms of patient 
outcome over the last two decades58,59. 
TNBCs account for 12% of IBCs and are so called because of the lack of  ER/PR 
overexpression and HER2-amplification. These tumors are more common in women 
with BRCA1 gene mutations and patients suffering from this disease have the poorest 
prognosis, due to the lack of effective targeted therapies60. In fact, chemotherapy still 
remains the main therapeutic option for TNBC patients60, with platinum having a 
specific role in patients carrying BRCA1/2 mutations or “BRCAness”61,62. However, 
several potentially actionable targets have been found in TNBC and new treatments 
targeting them are currently under clinical investigation such as PI3K, MEK and PARP 
inhibitors. Of note, the recently approved olaparib, a (PARP) inhibitor, in HER2-
negative, metastatic breast cancer provides an additional treatment option for patients 
with BRCA1/2 mutations or “BRCAness”63. 
4.1.4. The “molecular portraits” of human breast cancer 
The classical immunohistochemical markers ER, PR, and HER2, together with the 
standard clinicopathological features such as tumor size and grade, are routinely used 
for the management and prognosis of the patients. However, the fact that tumors of 
the same molecular subtype display variable responses to treatment have raised 
questions regarding the reproducibility and accuracy of disease prognosis and 
therapeutic decision making based only those makers64. Methods to classify tumors 
based on their gene expression signatures using unsupervised or supervised 
clustering have been developed more than 20 years ago65. The rationale was to 
classify tumors into subtypes distinguished by significant differences in their gene 
expression profiles. The use of gene expression arrays first39,47, and of DNA and RNA 
sequencing later66,67, has revealed the “molecular portraits” of breast cancers and 
allowed a new sub-classification suggesting new potential biological interpretation of 
their heterogeneity. In particular, the pioneer works of Perou et al.39 followed by the 
ones of Sørlie et al.47 have led to the classification of breast cancer into five intrinsic 
subtypes with distinct clinical outcomes: luminal A, luminal B, HER2-overexpression, 





basal and normal-like tumors (Table 2). Each of the five intrinsic subtypes is nicely 
mapped to the already established IHC subtypes, with the only exception being 
represented by the normal-like subtype which accounts for 7.8% of all breast cancer 
cases and shows an IHC status similar to the luminal A subtype even if is characterized 
by a normal breast tissue profiling. 
 
TABLE 2. Summary of breast tumor molecular subtypes.  
 
 
The gene expression profiling of breast tumors has led to some important 
considerations. First of all, the surprisingly large-scale molecular differences between 
ER-positive and ER-negative cancers suggested that these two different types of 
breast cancers are fundamentally two distinct diseases68, as they are now considered 
in the clinic. Another important implication derived from these pioneer microarray 
studies was that ER-negative breast carcinomas encompass at least two additional 
molecular subtypes: basal-like and HER2 overexpressed subtype, which also needs 
to be treated as distinct diseases39. 
The complexity and heterogeneity of this disease has emerged with more 
evidence when almost a decade later Parker et al.69 developed a standardized subtype 
classifier based on the expression of 50 genes (PAM50) mostly containing hormone 
receptor, proliferation related genes and genes exhibiting myoepithelial and basal 
features. Initially developed on microarray data, the PAM50 has been successfully 
used in multiplexed gene expression platforms such as NanoString70, qRT-PCR71 and 
RNA sequencing72. In combination with clinical factors (e.g. tumor size), it has been 
approved for the prediction of risk of distant relapse in ER-positive post-menopausal 
patients73 and is also routinely used as an indicator for adjuvant therapy73,74. 





Analyses on primary breast cancer data from The Cancer Genome Atlas (TCGA) 
have provided key insights into previously defined gene expression subtypes and the 
mutational landscape of breast tumors. In particular, it has shown that several 
significantly mutated genes display mRNA-subtype-specific and clinical-subtype-
specific patterns of mutation. Specifically, the luminal A subtype harbored the most 
significantly mutated genes, with the most frequent being PIK3CA (45%), followed by 
MAP3K1, GATA3, TP53, CDH1 and MAP2K4. Luminal B cancers exhibited a diversity 
of significantly mutated genes, with TP53 and PIK3CA (29% each) being the most 
frequent. The luminal tumor subtypes markedly contrasted with basal-like cancers 
where TP53 mutations occurred in 80% of cases. The HER2-enriched subtype had a 
hybrid pattern with a high frequency of TP53 (72%) and PIK3CA (39%) mutations and 
a much lower frequency of other significantly mutated genes including PIK3R1 (4%). 
Additionally, this analysis identified specific signalling pathways dominant in each 
molecular subtype including an HER2/phosphorylated HER2/EGFR/phosphorylated 
EGFR signature within the HER2-enriched expression subtype. Further studies 
demonstrated that genome copy number alterations (CNAs) dominate the genomic 
landscape of breast cancer66,67, thus supporting the biological relevance of a copy 
number-based classification of breast cancers. In the work of Curtis et al. 
unsupervised analysis of paired DNA–RNA profiles of 2,000 breast tumors showed 
that genome CNAs differ among different expression subtypes and revealed novel 
subgroups with distinct clinical outcomes66. Their results provide a novel molecular 
stratification of the breast cancer population, derived from the impact of somatic CNAs 
on the transcriptome. The new classification comprises 10 subtypes (IntClust 1-10)66, 
which has been further validated in 7,500 tumors and shown to be reproducible in a 
large meta-analysis and clinically valid75.  
Pereira et al.67 went further into the analysis and sequenced 173 genes in 2,433 
primary breast tumors (METABRIC)66 for which CNAs, gene expression and clinical 
data were already available. This study has led to the identification of 40 mutation-
driver (Mut-driver) genes and determined an association between those drivers, CNA 
profiles, clinicopathological data, and survival. As previously described, PIK3CA 
(40.1%) and TP53 (35.4%) were identified as the most common coding mutated genes 





and only 5 other genes were found to be mutated in at least 10% of the patients, 
among which GATA3 (11.1%)67.  
4.1.5. Estrogen receptor positive breast cancers and endocrine therapy 
resistance 
Estrogen receptor expression is reported in 70% of breast cancer cases76. As 
described above, genome-wide gene expression analyses have led to the sub-
classification of estrogen receptor-positive breast cancer into two “intrinsic” subtypes: 
luminal A and luminal B39,47,77. Luminal A tumors show the highest expression of ER 
and its associated genes. Luminal B tumors instead show a low-to-moderate 
expression of luminal genes and express some genes normally expressed in ER-
negative breast cancers. Moreover, tumors of luminal B subtype harbor TP53 
mutations more frequently than luminal A subtype39,78 and patients with luminal B 
tumors have significantly worse relapse-free and overall survival compared to luminal 
A subtype patients39,47,77.  
Estrogen receptor is the primary therapeutic target in breast cancer. Many drugs 
have been developed against ER, with tamoxifen79 and fulvestrant80 being current 
pillars of breast cancer treatment. In fact, virtually all patients diagnosed with ER-
positive breast cancer are eligible for endocrine therapy. The relevance of ER positivity 
in relation to responsiveness to endocrine therapy has been well established and 5 
years of adjuvant tamoxifen indeed reduces 15-year risks of breast cancer recurrence 
and death to less than 25% in ER-positive breast cancer patients81. Therefore, ER 
testing is currently recommended for all invasive breast cancers in order to guide 
therapeutic decisions.   
Up to 50% of early stage breast cancer patients develop disease recurrence 
despite local therapy and long term adjuvant endocrine treatment81,82.  In the context 
of ER-positive breast cancer, this is mainly due to the development of de novo or 
acquired resistance to anti-ER treatment respectively in 30% and 40% of cases. The 
European Society for Medical Oncology (ESMO) consensus guidelines for advanced 
breast cancer define acquired endocrine resistance as a relapse after the first 2 years 
of adjuvant endocrine treatment, a relapse within 12 months of completing adjuvant 
endocrine treatment, or progressive disease greater than 6 months after initiating 
endocrine therapy for metastatic breast cancer (MBC)83. Differentiating endocrine-





responsive versus endocrine-resistant tumors is clearly a primary need for clinicians 
who hope to spare unnecessary chemotherapy to endocrine-responsive patients. 
Indeed, chemotherapy is still the current standard of care in endocrine-resistant 
patients, even though it is not very effective on ER-positive breast cancer84,85.   
The principal causes of endocrine resistance are somatic mutations of the  ESR1 
gene (encoding for estrogen receptor alpha) or functional Annotation of ESR1 Gene 
Fusions  and recurrent hyperactive ESR1 fusion proteins under the pressure of 
estrogen deprivation therapy86,87.  These alterations tend to occur in the ligand-binding 
domain of ER, causing its constitutive activation and leading to estrogen-independent 
tumor growth. While ESR1 mutations are rare in treatment-naive tumors, the same 
mutations are more frequently observed in MBC patients pre-treated with endocrine 
therapy86,88,  with 20% of them developing ESR1 mutations during endocrine 
therapy89. This is one of the main reasons why MBC remains incurable, with a median 
5-year survival rate of less than 25%. 
 
Another important biomarker of response to endocrine therapy in clinical practice 
is HER2. Approximately 10% of ER-positive breast cancers have HER2 gene 
amplification (luminal B subtype)90 and HER2 positivity is commonly recognized to be 
a marker of endocrine resistance and poor prognosis91.  In large clinical studies, HER2 
positivity has been associated with reduced benefit to both tamoxifen and letrozole, 
suggesting intrinsic therapeutic resistance92,93,94.  Fortunately and as already 
mentioned, those patients can benefit from anti-HER2 treatment which improves the 
outcome of HER2-positive patients regardless of ER status95. 
4.1.6. GATA3 
GATA-binding protein 3 (GATA3) is 1 of 6 members of the GATA family of zinc-
finger transcription factors, so named because of their ability to bind to the DNA 
consensus 5′-(A/T) GATA (A/G)-3′ motif96,97.  In addition to their zinc-finger motif,  
GATA factors share two transactivation domains at the amino terminus and a 
conserved basic region that is located immediately after each zinc finger motif (Figure 
4.3.). At the amino acid level, the family members share varying degrees of homology, 
from 55% between GATA2 and GATA3 to only 20% between GATA3 and GATA4. 





However, the zinc finger motifs are about 80% homologous among all the six 
members. 
GATA factors are all involved in cell differentiation, proliferation, and movement 
control96 and are expressed in a tissue-specific manner. GATA1 and GATA2 are 
expressed primarily in hematopoietic cells, whereas GATA4, GATA5, and GATA6 are 
expressed in mesoderm- and endoderm-derived tissues such as heart, liver, and 
intestine. GATA3, instead, was first identified in the T cell lineage98,99 where it plays 
an essential role in early T cell development100. Later, it was discovered that GATA3 
also performs critical functions outside of the hematopoietic system, regulating the 
specification and differentiation of many different tissue types101,102 such as adipose 
tissue103, endothelial cells104, mammary gland105–107, thymocytes100,108, and 
others108,109,110. As a proof of the key role of GATA3 in development, haploinsufficiency 
of GATA3 results in the abnormal organ development responsible for the autosomal 
dominant human Barakat or HDR syndrome characterized by hypothyroidism, 
sensorineural deafness and renal anomaly (HDR)111 and Gata3 null embryos die 
between E11 and E12 due to internal bleeding, display growth retardation, deformities 
in the brain and spinal cord and gross aberrations in fetal liver hematopoiesis112.  
 
FIGURE 4.3. Schematic representation of GATA3 protein. Created with Biorender.com. 
 
In the breast, GATA3 plays a specific role in the differentiation of the breast luminal 
epithelial cells105,113,114. The mammary epithelium consists of a dual layer of epithelial 
cells, luminal and myoepithelial, that originate from a common progenitor but are 
specified by distinct pathways. The luminal epithelial cells that line the ductal 
epithelium and secrete milk proteins express GATA3. These cells are surrounded by 
a basal layer of myoepithelial cells, which do not express GATA3 (Figure 4.4.). Both 





cell types arise from a multipotent progenitor population that has been recently 
characterized115,116.  Shortly after the onset of puberty, specialized structures known 
as terminal end buds (TEBs) develop at the invading epithelial tips of the mammary 
epithelium. TEBs contain an outer layer of cells, which are believed to be myoepithelial 
progenitors, and a multilayered inner core of cells, which contains the luminal cell 
progenitors. TEBs proliferate and invade into the fatty stroma of the mammary gland 
in a process known as branching morphogenesis. Microarray profiling of the TEBs 
versus mature epithelial ducts versus the stroma shows that GATA3 is the most highly 
expressed transcription factor in the mammary epithelium 105. Using a mammary 
epithelium-specific knockout of Gata3, it has been shown that GATA3 is necessary for 
mammary gland development105,113. In particular, the mammary glands of Gata3-KO 
mice fail to develop TEBs and the epithelium fails to invade the stroma (Figure 4.4.) 
thus suggesting a role for GATA3 in ductal elongation and branching.  
FIGURE 4.4. GATA3 in normal mammary gland development. (A) A schematic 
representation of the mammary epithelium and stroma during mammary gland development. 
The luminal epithelial cells, in yellow, express GATA3 while the myoepithelial cells, in red, 
express very low levels of GATA3. (B) Whole-mount carmine red staining of mouse mammary 
glands from 5-week-old wild-type (left) and Gata3 conditional knock-out (CKO) (right) mice 
outlines the epithelium. In the wild-type mammary gland, the epithelium has invaded into the 
stroma, with multiple TEBs formed. By contrast, the Gata3-CKO mammary gland shows a 
defect in the epithelial invasion into the stroma. Scale bar corresponds to 3mm. Part (A) is 
modified from Lu and Werb (2008) and (B) is 
reprinted from Kouros-Mehr et al. (2006). 
 
 
Considering the ability of GATA factors 
to coordinate cellular maturation and 
proliferation, it is not surprising that these 
genes have been found to play a role in 
cancer. 
In breast cancer, GATA3 expression 
level is strongly associated with the 
estrogen receptor α (ERα) expression and 
is diagnostic of the Luminal A and Luminal 
B subtypes. The highest expression of 
GATA3 in breast tumors is indicative of 





good outcome while when GATA3 levels lower, the prognosis worsens47,77,117,118. This 
is probably due to the suppressor role that GATA3 plays in the epithelial-to-
mesenchymal transition119–121. In fact, in a mouse model of breast cancer it has been 
shown that  GATA3 expression is lost as luminal epithelial cells lose their differentiated 
status and progress toward metastasis122. We know now that GATA3 is able to 
suppress epithelial-to-mesenchymal transition acting as a pioneer factor to recruit 
other co-factors such as ERα and FOXA1 in breast cancer cells123,124.  Strikingly, 
failure to respond to hormonal therapy and poor prognosis are also associated with 
the lack of GATA3 expression125. 
.  
GATA3 is one of the most frequently mutated genes in ER-positive breast 
cancers, with mutations found in 15% and 18% of primary and metastatic ER-positive 
breast cancers, respectively67,126. Mutations in GATA3 have not yet been extensively 
characterized, but the non-uniform distribution and mutual exclusivity with mutations 
in other cancer genes are strong indicators of the role of GATA3 as a cancer driver 
gene67,127. Almost all mutations affect exons 5 and exon 6 of the GATA3 gene, coding 
for the second zinc finger and the not well-characterized carboxyl terminus (Figure 
4.3.). Three major classes of mutations have been described so far: (1) splice site 
mutations at the exon 4/5 junction and the exon 5/6 junction, (2) frameshift mutations 
in exon 6, and (3) frameshift mutations in zinc finger 2 (Figure 4.3.). Most of the 
mutations in GATA3 are limited to a single allele, and the expression of both the 
mutated and wild-type alleles is approximately equal. 
Considering the prognostic role of GATA3 expression, its role in differentiation and 
metastasis suppression, and the fact that the vast majority of GATA3 mutations are 
frameshift mutations (i.e. expected to be loss-of-function), GATA3  has long been 
considered a tumor suppressor gene in breast cancer. However, GATA3 has been 
shown to have oncogenic activity in other human cancers101 and more recently 
putative oncogenic roles for GATA3 have been also reported in breast. These 
observations together with the haploinsufficiency of GATA3 mutations raise important 
questions regarding the nature of those mutations in breast cancer. Recently, the 
pioneer work of Mair et al.128 sub-grouped GATA3 mutations into two distinct functional 
classes leading to either gain- or loss- of function activities. In particular, they showed 





that GATA3 frameshift mutations leading to an extended protein (GATA3-ext) may 
occur and are mechanistically distinct from truncating and wild-type proteins. In 
patients, GATA3-ext is associated with the differential expression of a distinct group 
of response genes that is not affected by other GATA3 mutants. Taken together, these 
lines of evidence provide substantial support for the hypothesis that GATA3-ext may 
have additional functions compared to the wild-type GATA3. Those findings certainly 
challenge the classical view according to which GATA3 only acts as a tumor 
suppressor that is down-regulated or inactivated in breast cancer. 
 
Although it is becoming evident that the role of GATA3 in the development of 
cancer is more complex than expected, its tumor suppressor role is still the most widely 
accepted. Overall, there is no doubt about the fact that GATA3 is a master regulator 
of breast tissue and plays a pivotal role in the biology of breast cancer. Unfortunately 
targeted therapies directed at GATA3 deficiency are not available. In this project, I 
focused on targeting tumors with GATA3 frameshift mutations resulting in protein 
truncation and its consequent loss-of-function. In particular, I studied a new synthetic 
lethal interaction between these specific mutations occurring in patients and the use 
of nutlin inhibitors as a viable therapeutic opportunity.  
4.1.7. Synthetic lethality and context-dependent genetic interactions in cancer 
Tumor genetic alterations are broadly classified into gain-of-function alterations in 
growth-enhancing oncogenes and loss-of-function alterations in growth-inhibitory 
tumor suppressor genes (TSG), as well as so-called “passenger” mutations which 
arise randomly as a result of impaired DNA repair but do not contribute to 
oncogenesis129. Targeting oncogenes with either small molecule inhibitors or 
antibodies has proved to be highly effective as cancer therapy130 and represents the 
state-of-the-art of precision oncology131.  Loss-of-function mutations in TSGs are more 
difficult to target, as it is not feasible with our current technology to restore the function 
of mutated or deleted genes132. However, rather than targeting the mutated gene 
directly, an emerging strategy is to identify genetic interactors of that gene, such that 
simultaneous disruption of the function of both genes causes selective cell death. This 
concept is more broadly known as synthetic lethality (SL) and it refers to the biological 
context in which, given a pair of genes, aberration in either gene alone is innocuous 





while the simultaneous co-occurrence of aberrations in both genes is lethal to the cell 
(Figure 4.5.)133,134. Given that half of solid tumors may not harbor a known oncogenic 
genetic alteration129 and that not all oncogenic genetic alterations can be targeted by 
specific inhibitors, the synthetic lethal approach has been proposed as a way to extend 
precision oncology to a significantly larger proportion of cancer patients135. Synthetic 
lethality refers to the principle by which secondary addictions can be exploited 
therapeutically by inhibiting the remaining vital pathway.  
 
FIGURE 4.5. Classes of tumor specific vulnerabilities. Genotype-specific synthetic lethal 
interaction (A) involves a loss-of-function mutation or deletion in a tumor suppressor gene 
(GENE A); when the partner gene (GENE B) is inhibited with a drug the function of both genes 
is lost in the tumor cell with lethal effect. Non-tumor cells, which retain function of GENE A, 
remain viable. (B) Resistance to drugs ('Drug A' targeting 'oncoprotein A') can occur through 
feedback-mediated activation of the same or a parallel signalling pathway ('pathway B'). This 
drug-specific synthetic lethality can be exploited using combination therapy targeting both 
signalling nodes (drugs A and B) to overcome resistance. Created with Biorender.com. 
The use of PARP inhibitors in BRCA-mutated cancer is a prominent example of 
the concept of synthetic lethality136. The BRCA1 and BRCA2 genes are involved in the 
DNA double-strand breaks repair by homologous recombination137 and are often 
mutated in breast and ovarian cancers138–140. Cancer cells with an impaired DNA 
damage repair pathway normally become addicted to an alternative DNA damage 
repair pathway. In particular, cancer cells harboring a mutation in the BRCA1/2 genes 
continue to replicate relying on the base excision repair (BER), the single-strand break 
(SSB) repair and the alternative non-homologous end-joining (Alt-NHEJ)141–143. 
Several important mediators of these pathways play a role in more than one pathway, 
among which is the gene poly(ADP-ribose) polymerase 1 (PARP1)144,145. This 





knowledge has led to the emergence of a synthetic lethal approach targeting PARP1 
(and other PARPs) in cancers deficient in BRCA1 or BRCA2146. In these cells, if 
PARP1 is inhibited, the cell loses its ability to repair DNA breaks and as a result, the 
BRCA-mutated cells (tumor cells) undergo apoptosis, whereas normal cells with intact 
BRCA are able to repair the double-strand DNA lesions and survive147.  
4.1.8. Large-scale perturbation screens for the identification of synthetic lethal 
vulnerabilities 
The first high-throughput genetic interaction studies, named synthetic genetic 
arrays, were conducted in yeast. In synthetic genetic arrays a query mutant yeast 
strains is crossed to an array of gene-deletion mutants to identify synthetic lethal 
interactions148,149. Since then, the advent of RNA interference (RNAi) has allowed the 
first high-throughput studies in multicellular organisms, first in C. elegans150, D. 
melanogaster151,152, and mouse153, and more recently in human153,154. Clustered 
Regularly Interspaced Short Palindromic Repeats  (CRISPR)–Cas9 screens have also 
emerged as a powerful tool to map genetic interactions 155. With this approach a large 
map of genetic interactions in cancer cells was recently described by Horlbeck et al. 
recently described a large map of genetic interactions by systematically perturbing 
222,784 gene pairs in two cancer cell lines156. In addition, computational approaches 
have been developed to infer genetic interactions from high-throughput sequencing 
data by examining co-occurring and mutually exclusive pairs of mutations157. Further, 
considerable efforts have gone into developing methods able to integrate mutational 
data with perturbation data158,159.   
McDonald et al.160 conducted a large-scale deep RNAi screen assessing the 
effects of ~8000 genes on the viability in 398 cell lines derived from the comprehensive 
collection of the Cancer Cell Line Encyclopedia160,161. This recently published 
compendium of cancer dependencies named Project DRIVE provides a rich and 
robust dataset for the identification of SL pairs. 
Using the recently developed SLIdR (Synthetic Lethal Identification in R; 
manuscript under review) algorithm on the breast cancer cell lines (n=22) in the Project 
DRIVE, we identified MDM2 as a selective vulnerability in GATA3-mutant breast 
cancer.   





4.1.9. MDM2, its role in cancer and the development of nutlins   
Mouse double minute 2 homolog (MDM2) is a protein that is encoded by the 
human gene MDM2. MDM2 was originally cloned as a highly amplified gene from the 
spontaneously transformed murine cell line BALB/c 3T3162. The MDM2 protein can 
form homo- or hetero-oligomers with its homolog MDMX through its RING domain. 
The homo-/hetero-oligomer possesses an E3 ubiquitin ligase 163,164 through which 
MDM2 regulates the stability of various targets, among which is p53. Inhibition of p53 
transcriptional activation was the first functional role ascribed to MDM2 identified by 
Momand et al. in 1992165. In normal cells, both MDM2 and MDMX not only ubiquitinate 
p53 but can also inhibit its transactivation function by engaging its amino-terminal 
transactivation domain166,167.  Moreover, MDM2 is also essential for regulating p53 
function by mediating its export from the nucleus168. 
MDM2 and p53 tightly regulate each other by forming a complex negative-
feedback loop in which p53 induces the expression of MDM2, which in turn promotes 
the degradation of p53 and quenches its activity163 (Figure 4.6.).  
 
FIGURE 4.6. Autoregulatory feedback loop of p53 and MDM2. p53 stimulates the expression 
of MDM2; MDM2, in turn, inhibits p53 activity by stimulating its degradation, blocking its 
transcriptional activity, and promoting its nuclear export. Created with Biorender.com. 
 
The suppression of p53 activity is crucial during embryonic development169 and 
amplification or upregulation of the MDM genes is a common feature in cancer170–175. 
Various mechanisms that regulate MDM2 expression have been described. Most of 
the research has focused on single-nucleotide polymorphisms of the MDM2 promoter. 





In particular, SNP309 and SNP285 have been shown to affect cancer risks through 
the modulation of the Sp1 transcription-factor binding176–178. MDM2 levels are also 
regulated at the post-transcriptional level by microRNAs179. 
In human cancers, MDM2 amplification or overexpression has been associated 
with poor prognosis180 (especially in liposarcomas181–183, glioblastomas184–186, 
leukemias187–189 and solid tumors of the  stomach190)  and its overexpression also 
correlates with distant metastasis191–193. 
In many cases, the frequency of MDM protein deregulation is higher in tumors that 
retain wild-type p53194, pointing to the block of p53 transcriptional activity as the major 
oncogenic role of MDM proteins. However, MDM2 is reported to ubiquitinate numerous 
targets in addition to p53, for example, MDM2 binds to and ubiquitinates estrogen 
receptor and androgen receptor195–197. Moreover, both MDM2 and MDMX are 
overexpressed in some TP53-mutant tumors thus suggesting that both proteins may 
have p53-independent roles in tumorigenesis, as discussed in recent reviews198,199. A 
clear proof of this comes from mouse models, where, in some cases, overexpression 
of Mdm2 leads to tumor development even in the absence of p53198–200. Additionally, 
the finding that MDM2 splice variants unable to bind p53 can still promote 
tumorigenesis further supports p53-independent roles for MDM2198,201. 
 
The MDM family and p53 are vital for normal breast morphogenesis. The 
importance of a strict regulation of MDM2 and p53 in the developing breast has been 
demonstrated and an excess of p53 activity in the mammary gland has been 
associated with reduced growth202,203. Intriguingly, hormone stimulation (such as 
estrogen and progesterone) can overcome the growth inhibition imposed by elevated 
p53 levels and estrogen can boost MDM2 levels by binding its promoter204–206. In turn, 
MDM2 can also regulate ERα levels by promoting its transcription in a p53-
independent manner195,205. Conversely, MDM2 appears to drive the proteasomal 
degradation of both p53 and ERα when they co-complex207, thus suggesting that the 
relationship between MDM2, ER and p53 in breast tissue homeostasis is vital and 
based on a delicate balance between the different interactors. In this context, it is not 
hard to imagine that MDM family deregulation may play an important role in the 
development of breast cancer. The development of ductal hyperplasia in transgenic 





mice overexpressing Mdm2  is a direct evidence of the oncogenic capacity of MDM2 
in the mammary tissue202,207. Elevated MDM2 protein levels have been reported in 
breast cancers and have been identified as an independent prognostic biomarker208. 
Of note, and in line with the tight regulation between ER, MDM2 and p53, 
overexpression of MDM2 oncoprotein correlates with expression of ERα78,187,209. 
Further, consistent with literature findings, TP53 mutations, and MDM2 amplifications 
are mutually exclusive across the breast cancer subtypes78,210209–212. 
Roughly half of all cancers harbor mutant forms of p53213. The remaining 50% of 
tumors expressing wild-type p53 are potential targets for therapies aimed at 
reactivating p53 function among which MDM inhibitors are up to now the most 
promising therapeutic option. Currently, there are multiple small-molecule inhibitors of 
the MDM2–p53 interaction, and some advanced compounds are already in phase III 
clinical trials214. In 2004, a group of small-molecule antagonists known as nutlins was 
generated215. Nutlins target the MDM2 N-terminal p53-binding pocket and, hence, 
displace and activate p53216. Since the development of nutlins, several companies 
have developed their own MDM2 inhibitors such as CGM097 and HDM201 from 
Novartis217, SAR405838 from Sanofi218,219 and others220–224. The high doses required 
together with the toxicities and complications attributable to the administration of first-
generation nutlins have prompted the development of a more potent and selective 
compound in the nutlin family named RG-7388 (RO5503781, Hoffmann-La Roche) 
known as idasanutlin. Idasanutlin is a second-generation MDM2 inhibitor able to 
induce the expected biological effects at concentrations significantly lower than those 
required by  first-generation nutlins225. Owing to the high efficacy and fewer side 
effects, RG-7388 has accelerated through the initial phases of clinical trials and has 
now reached phase III clinical trials in patients with relapsed or refractory acute 
myeloid leukemia214. Although idasanutlin has proven efficacy mainly in hematological 
malignancies, clinical trials have been conducted (NCT03362723, NCT02828930) or 
are actively recruiting patients with solid tumors (NCT03337698, NCT03158389), 









4.2 Aim of the Research Project 
 
GATA3 is one of the most frequently mutated genes in estrogen positive breast 
cancers and its level of expression is strongly associated with ERα expression, thus 
being diagnostic as Luminal subtypes. Of note, low expression of GATA3 is indicative 
of poor prognosis and failure to respond to hormonal therapy is also associated with 
lack of GATA3 expression. Therefore, identification of new targeted therapies 
specifically directed against GATA3 loss of function mutations or loss of GATA3 
expression may be of particular relevance in the treatment of estrogen positive breast 
cancer.  
 
Using our in house developed algorithm to explore the data derived from the 
project DRIVE160 we aimed to identify potential synthetic lethal partners of GATA3 in 
estrogen positive breast cancer. More in detail, in the first part of the project we aimed 
to validate MDM2 as a synthetic lethal interactor of GATA3 in vitro combining multiple 
siRNAs in three different estrogen positive cell lines models. Additionally, we aimed to 
gain insight into the molecular mechanism underlying this synthetic lethal interaction 
and, in particular, if it was p53-dependent or independent. In the second part of the 
project we aimed to prove that the presence of GATA3 loss-of-function mutations as 
well as lowering of GATA3 expression are able to predict response to MDM2 inhibitors 










4.3. Methods  
4.3.1. Cell lines 
ER-positive breast cancer-derived cell lines MCF-7 (GATA3 mutant p.D335Gfs; 
TP53 wild-type), BT-474 (GATA3 wild-type, TP53 mutant p.E285K with retained 
transactivation activity226), MDA-MB-134 (GATA3 wild-type; TP53 wild-type) and T47D 
(GATA3 wild-type, TP53 mutant p.L194F) were kindly provided by Dr. Rachael 
Natrajan from The Institute of Cancer Research, Royal Cancer Hospital (London, UK), 
authenticated by short tandem repeat profiling as previously described and tested for 
mycoplasma infection using a PCR-based test (ATCC) as previously described227. All 
cells were monitored regularly for mycoplasma contamination as described above. All 
cell lines were maintained under the condition as recommended by the provider. 
Briefly, all cell lines were cultured in DMEM supplemented with 5% Fetal Bovine Serum 
(FBS), non-essential amino acids (NEAA) and antibiotics (Penicillin/Streptomycin). 
The cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. 
Exponentially growing cells were used for all in vitro and in vivo studies. 
4.3.2.Transient gene knockdown by siRNAs 
Transient gene knockdown was conducted using ON-TARGET plus siRNA 
transfection. ON-TARGET plus SMARTpool siRNAs against human GATA3 
(Dharmacon, CO; #L-003781-00-0005) and MDM2 (Dharmacon, CO; #L-003279-00-
0005),  ON-TARGET plus SMARTpool non-targeting control and DharmaFECT 
transfection reagent  (Dharmacon, CO; #T-2001-03) were all purchased from GE 
Dharmacon. Transfection was performed according to the manufacturer’s protocol. 
Briefly, log-phase ER-positive breast cancer cells were seeded at approximately 60% 
confluence. Because antibiotics affects the knockdown efficiency of ON-TARGET plus 
siRNAs, growth medium was removed as much as possible and replaced by antibiotic-
free complete medium. siRNAs were added to a final concentration of 25 nM. (Note: 
siRNAs targeting different genes can be multiplexed). Cells were incubated at 37°C in 
5% CO2 for 24-48-72 hours (for mRNA analysis) or for 72 hours (for protein analysis). 
To avoid cytotoxicity, the transfection medium was replaced with complete medium 
after 24 hours.  





4.3.3. RNA extraction and relative expression by qRT-PCR 
Total RNA was extracted from cells at 75% confluence using TRIZOL (Invitrogen, 
Carlsbad, CA, USA) according to manufacturer's guidelines. cDNA was synthesized 
from 1 μg of total RNA using SuperScript™ VILO™ cDNA Synthesis Kit (Invitrogen).  
All reverse transcriptase reactions, including no-template controls, were run on an 
Applied Biosystem 7900HT thermocycler. Gene expression was assessed by using 
FastStart Universal SYBR Green Master Mix (Merk, CO; #4913850001) and all qPCR 
performed were conducted at 50°C for 2 min, 95°C for 10 min, and then 40 cycles of 
95°C for 15 s and 60°C for 1 min on a QuantStudio 3 Real-Time PCR System (Applied 
Biosystems). The specificity of the reaction was verified by melting curve analysis. 
Measurements were normalized using GAPDH level as reference. The fold change in 
gene expression was calculated using the standard ΔΔCt method as previously 
described.228 All samples were analyzed in triplicate using the following primers: 
 
4.3.4. Immunoblot 
For immunoblot total protein was harvested by directly lysing the cells in Co-IP 
lysis buffer (100 mmol/L NaCl, 50 mmol/L Tris pH 7.5, 1 mmol/L EDTA, 0.1% Triton X-
100) supplemented with 1x protease inhibitors (cOmplete™, Mini, EDTA-free Protease 
Inhibitor Cocktail, Roche, CO; #4693159001) and 1x phosphatase inhibitors 
(PhosSTOP, CO; #4906845001). Cell lysates were then treated with 1x reducing agent 
(NuPAGE Sample Reducing Agent), 1x loading buffer (NuPAGE LDS Sample Buffer), 
boiled and loaded onto neutral pH, pre-cast, discontinuous SDS-PAGE mini-gel 
system (NuPAGE 10% Bis-Tris Protein Gels). After electrophoresis, the proteins were 





transferred to nitrocellulose membranes using Trans-Blot Turbo Transfer System (Bio-
Rad). The trans-blotted membranes were blocked for 1 hr in TBST 5% milk and then 
probed with appropriate primary antibodies (from 1:200 to 1:1000) overnight at 40°C 
(antibodies are listed in the table below).  Next, the membranes were incubated  for 1 
hour at room temperature with fluorescent secondary goat anti-mouse (IRDye 680) or 
anti-rabbit (IRDye 800) antibodies (both from LI-COR Biosciences). Blots were 
scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences) and band 
intensity was quantified using ImageJ software 1.51i . The ratio of proteins of 
interest/loading control in treated samples were normalized to their counterparts in 
control cells.  
 
4.3.5. Drug treatment 
Exponentially growing cells were plated at a density of 10x103 cells in a 96-well 
plate. After 24 hours, cells were treated with serial dilution of RG7388-idasanutlin 
(Selleckchem, CO; #S7205) or dimethyl sulfoxide (DMSO). DMSO served as the drug 
vehicle, and its final concentration was no more than 0.1%. Cell viability was measured 
after 72 hours using CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega, 
CO; #G7570). Results were normalized to vehicle (=100% DMSO). Curve fitting was 
performed using Prism (GraphPad) software and the nonlinear regression equation. 
All experiments were performed at least  twice in triplicate. Results are shown as mean 
± SD. 
4.3.6. Proliferation assay 
Cell proliferation was assayed using the xCELLigence system (RTCA, ACEA 
Biosciences, San Diego, CA, USA) as previously described.229 Cells were first seeded 
and transfected in 6 well plates and 24 h after transfection 5x103 cells were 





resuspended in 100 μl of medium and plated in each well of an E-plate 16. Background 
impedance of the xCELLigence system was measured for 12 s using 50 μl of room 
temperature cell culture media in each well of E-plate 16. The final volume in each well 
was then 150 μl. The impedance signals were recorded every 15 minutes until 96/120 
h and expressed as cell index values, calculated automatically and normalized by the 
RTCA Software Package v1.2. The values were defined as mean ± standard deviation. 
Mann-Whitney test was used for statistical analysis with GraphPad Prism 7 software. 
4.3.7. Apoptosis analysis by flow cytometry 
Cells were collected 72 hours post siRNA transfection and 48 hours post treatment 
with RG7388 respectively, stained with annexin V (Annexin V, FITC conjugate; 
Invitrogen, CO; #V13242) and propidium iodide (PI; Invitrogen, CO; #V13242), and 
analyzed by flow cytometry using the BD FACSCanto II cytometer (BD Biosciences, 
USA). Briefly, cells were harvested after incubation period and washed twice by 
centrifugation (1,200 g, 5 min) in cold phosphate-buffered saline (DPBS; Gibco, CO; 
#14040133). After washing, cells were resuspended in 0.1 mL  AnnV binding buffer 1X 
(ABB 5X, Invitrogen, CO; #V13242; 50 mM HEPES, 700 mM NaCl, and 12.5 mM 
CaCl2 at pH 7.4) containing fluorochrome-conjugated AnnV and PI (PI to a final 
concentration of 1 ug/mL) and incubated in darkness at room temperature for 15 min. 
As soon as possible cells were analyzed by flow cytometry, measuring the 
fluorescence emission at 530 nm and >575 nm. Data were analyzed by FlowJo 
software version 10.5.3 (https://www.flowjo.com).  
4.3.8. Zebrafish xenografts 
Animal experiments and zebrafish husbandry were approved by the “Kantonales 
Veterinaeramt Basel-Stadt”. 48 hours post siRNA transfection, GATA3 silenced and 
control BT-474 cells were pre-treated for 24 hours with idasanutlin (25 μM). After 
harvesting, the cells were labeled with a lipophilic red fluorescent dye (CellTracker™ 
CM-DiI #C7000; Life Technologies, Darmstadt, Germany), according to the 
manufacturer's instructions. Wild-type zebrafish were maintained, collected, grown 
and staged in E3 medium at 28.5°C according to standard protocols230. For 
xenotransplantation experiments, zebrafish embryos were anesthetized in 0.4% 





tricaine (Sigma) at 48 hours post fertilization (hpf) and 200 control or GATA3 silenced 
BT-474 cells were micro-injected into the vessel-free area of the yolk sac. Embryos 
were incubated for 1 hour at 28.5–29°C for recovery and cell transfer verified by 
fluorescence microscopy. Fish harboring red cells were incubated at 35°C as 
described previously231,232. On assay day 3, embryos were screened microscopically 
for tumor cell engraftment using a Nikon CSU-W1 spinning disk microscope 
microscope and the number of tumor-bearing fish quantified. Fish were furthermore 
dissociated into single cells as described previously233,234 and cells analyzed on a BD 
FACSCanto II cytometer for CM-DiI–positive cells. For each condition, 20 to 30 fishes 
were analyzed. Each experiment was repeated twice. 
4.3.9. Quantification and statistical analysis 
Statistical analyses were conducted using Prism software v7.0 (GraphPad 
Software, La Jolla, CA, USA). Statistical significance was determined by the two-tailed 
unpaired Student’s t-test. A p-value < 0.05 was considered statistically significant. For 
all figures, NS, not significant, *p<0.05, **p<0.01, ***p<0.001. The statistical 
parameters (i.e., exact value of n, p values) have been noted in the figures and figure 
legends. Unless indicated, all data represent the mean ± standard deviation from at 
least three independent experiments. 
  






4.4.1. Identification of MDM2 as a putative synthetic lethal interactor of GATA3 
in breast cancer cell lines 
 
The recently published compendium of cancer dependencies Project DRIVE 
profiled 398 cancer cell lines in the comprehensive collection of the Cancer Cell Line 
Encyclopedia235,236 using an RNA interference library targeting ~8000 genes to assess 
the effect of these genes on cell survival235,236. Large-scale perturbation screens are 
highly informative about SL, and their full potential is yet to be exploited, therefore we 
investigated the data generated by McDonald et al.235,236 to discover potentially 
targetable synthetic lethalities and selective vulnerabilities in cancer and, in particular, 
in GATA3-mutant breast cancers. Together with the bioinformatic research group of 
Prof. Niko Beerenwinkel, ETH Zurich, we recently submitted a manuscript on the 
development of a new statistical method called SLIdR (Synthetic Lethal Identification 
in R) for predicting SL partners from large-scale perturbation screening data in both 
pan-cancer and cancer-specific settings (Srivatsa S., Montazeri H., Bianco G. et al., 
manuscript submitted, see “other achievements” of the present thesis). The SLIdR 
algorithm provides a rank-based statistical framework to identify the presence of a 
synthetic lethal dependency between a driver gene and a perturbed gene. Using this 
recently developed algorithm on the breast cancer cell lines (n=22) in the Project 
DRIVE, we identified MDM2 and UBE2D3 as selective vulnerabilities in breast cancers 
with GATA3 loss-of-function somatic mutation. (Figure 4.7., A-C).  
 
 





Figure 4.7. The SLIdR algorithm identified MDM2 as a selective vulnerability in breast 
cancers with GATA3 loss-of-function somatic mutation.  (A) Viability scores of GATA3 
mutant vs WT breast cancer cell lines with MDM2 knockdown. (B) -log10(P) of the SLIdR 
algorithm plotted against the mean difference in viability between GATA3-mutant and wild-
type breast cancer cell lines. Genes with q-value < 0.1 are labeled. 
 
We found the lethal interaction between GATA3 and MDM2 particularly interesting 
considering that GATA3 mutations occur very frequently in ER-positive breast cancers 
and that MDM2 inhibitors are currently being evaluated in Phase III clinical trials. 
Therefore, we decided to further explore this discovery. We first sought to validate the 
predicted synthetic lethality between GATA3 and MDM2 in the ER-positive breast 
cancer cell line MCF-7, one of the two GATA3-mutant cell lines used in the pan-cancer 
screen236. MCF-7 carries the GATA3 frameshift mutation p.D335Gfs235, which has 
been recurrently observed in breast cancer patients. We silenced MDM2 expression 
using a pool of small interfering RNA (siRNA) directed against the MDM2 gene and 
showed that the siRNA approach effectively reduced MDM2 mRNA expression by 
more than 50% up to 72 hours post-transfection (Figure 4.7., A). MDM2 protein levels 
were also reduced by 50% by western blotting 72 hours post siRNA transfection. 
Evaluating cell viability through a cell proliferation assay we observed that MDM2 gene 
knock-down significantly impaired proliferation compared to control cells (Figure 4.7., 
B). In particular, cells started to proliferate less 12 hours post seeding (36 hours post 
siRNA transfection) up to 96 hours (120 hours post siRNA transfection), when their 
cell index decreased, thus suggesting not only cell proliferation arrest, but also cell 
death.  






FIGURE 4.8. MDM2 is synthetically lethal with GATA3 p.D335Gfs in MCF-7 breast cancer 
cells. (A) MDM2 mRNA level of expression (upper panel) in MCF-7 cells at 24, 48 and 72 
hours post siRNA transfection. Western blotting (lower panel) showing GATA3 mut, GATA3 
WT and MDM2 protein level of expression in MCF-7 cells 72 hours post siRNA transfection.  
(B) Proliferation kinetics of MCF-7 cells transfected with siRNA targeting MDM2 (light blue) or 
siRNA control (black). (C) Flow cytometry analysis of Annexin V and propidium iodide co-
staining to measure the percentage of apoptotic cells (AnnV+) and live cells (AnnV-/PI-) upon 
MDM2 silencing in MCF-7 cells. (D) MDM2 mRNA levels (upper panel) in MCF-7 cells 48 
hours after transfection with different concentrations of MDM2 siRNA (6.25 nM, 12.5 nM or 25 
nM). Western blotting (lower panel) showing MDM2 protein level of expression in MCF-7 cells 
72 hours after transfection with different concentrations of MDM2 siRNA (6.25 nM, 12.5 nM or 
25 nM). (E) Proliferation kinetics of MCF-7 cells transfected with MDM2 siRNA in different 
concentrations (6.25, 12.5 and 25 nM). (F) Flow cytometry analysis of Annexin V and 
propidium iodide co-staining to measure the percentage of apoptotic cells (AnnV+) and live 
cells (AnnV-/PI-) upon MDM2 silencing with different concentrations of siRNA in MCF-7 cells. 
 
To discriminate if MDM2 silencing was merely inhibiting cell growth or if it was also 
actively inducing cell death, we measured the percentage of apoptotic cells using 
Annexin V and propidium iodide (PI) co-staining followed by flow cytometry analysis 
(see methods). In particular, we counted cells positive for Annexin V only and for both 
Annexin V and PI as early and late apoptotic cells,  respectively. Cells negative for 
both were counted as living cells. We observed that MDM2 silencing significantly 
induced apoptosis in MCF-7 cells 72 hours post siRNA transfection (Figure 4.8,C). 





Additionally, to demonstrate that MDM2 inhibition was dose-dependent we performed 
a proliferation assay combined with MDM2 siRNA titration. We showed that the lethal 
effect induced by MDM2 inhibition in GATA3-mutant cells was dependent on the 
siRNA dose and the level of expression of MDM2 (Figure 4.8, E). In particular, the 
assay suggests that a 50% reduction in MDM2 expression is sufficient to induce 
synthetic lethality in the presence of GATA3-mutation (Figure 4.8, D). Similar results 
were obtained with apoptosis induction upon MDM2 siRNA titration (Figure 4.8, F). 
 
4.4.2. Dual inhibition of MDM2 and GATA3 in GATA3-wild-type cell lines 
confirms synthetic lethality 
The GATA3 frameshift mutation p.D335Gfs235 carried by the MCF-7 cell lines is a 
loss-of-function mutation leading to a truncated version of GATA3 which is unable to 
bind to and transactivate its target. Breast cancer patients normally harbor this 
mutation, and other frameshift mutations of GATA3, in heterozygosity and patients, as 
MCF-7 cells, still express the wild-type version of GATA3. However, It has also been 
reported that this GATA3 mutant is more stable at the protein level than wild-type 
GATA3 and that it can bind to and sequester wild-type GATA3, therefore acting as 
almost fully loss-of-function237. To exclude any gain-of-function effects of the GATA3 
mutant and to confirm that the apoptotic effect of MDM2 silencing was unequivocally 
related to GATA3 loss of function, we sought to validate the synthetic lethal interaction 
using a double siRNA approach in an ER-positive breast cancer cell lines wild-type for 
GATA3, the luminal A cell line MDA-MB134. We silenced GATA3 and MDM2 alone or 
in combination and assessed the cells for growth inhibition using the same 
experimental approach used in MCF-7. siRNA transfection led to a consistent 
reduction (50% to 90%) of both GATA3 and MDM2 mRNA levels up to 72 hours post-
transfection, as confirmed by qRT-PCR (Figure 4.9, A). Additionally, on the protein 
level, GATA3 and MDM2 expression were reduced from 60 to 90% by Western blotting 
(Figure 4.9, A). Of note, the silencing of both GATA3 and MDM2 significantly reduced 
cell proliferation compared to cells transfected with control siRNA, GATA3 siRNA or 
MDM2 siRNA alone (Figure 4.9, B). The result was even more striking considering 
that GATA3 silencing alone showed increased cell proliferation, consistent with the 
oncosuppressor role of GATA3 in breast cancer. We then asked if the synthetic lethal 





interaction was restricted to the luminal A ER-positive subtype or if it could be extended 
to the luminal B subtype, where GATA3 frameshift mutations also occur in patients. 
Therefore, we silenced GATA3 in the luminal B cell line BT-474 and obtained a 
significant reduction of GATA3 at both the mRNA and protein levels, comparable to 
that achieved in the MDA-MB134 cell line (Figure 4.9, C). As in MDA-MB134, GATA3 
silencing in combination with MDM2 silencing in BT-474 significantly reduced cell 
proliferation while GATA3 gene knock-down alone increased cell proliferation (Figure 
4.9, D).  
 
FIGURE 4.9: Dual inhibition of MDM2 and GATA3 in GATA3-wild-type cell lines confirms 
synthetic lethality. (A) MDM2 and GATA3 mRNA level of expression (top) in MDA-MB134 
cells at 24, 48 and 72 hours post siRNA transfection. Western blotting (bottom) showing 
GATA3 and MDM2 protein level of expression in MDA-MB134 cells 72 hours post siRNA 
transfection. (B) Effect of MDM2 and/or GATA3 silencing on proliferation in GATA3-wild-type, 
luminal A MDA-MB134 cell line. (C) MDM2 and GATA3 mRNA level of expression (top) in BT-
474 cells at 24, 48 and 72 hours post siRNA transfection. Western blotting (bottom) showing 
GATA3 and MDM2 protein level of expression in BT-474 cells 72 hours post siRNA 
transfection. (D) Effect of MDM2 and/or GATA3 silencing on proliferation in GATA3-wild-type, 
luminal B BT-474 cell line. (E) Flow cytometry analysis of Annexin V and propidium iodide co-
staining to measure the percentage of apoptotic cells upon MDM2 and GATA3 silencing, alone 
or in combination, in MDA-MB134 and BT-474 cells. 






As previously performed in MCF-7 cells,  to discriminate if the concomitant 
silencing of MDM2 and GATA3 was only inhibiting proliferation or was actively 
inducing cell death, we measured the percentage of apoptotic cells using Annexin V 
and FACS analysis. Consistent with the observations previously obtained in MCF-7 
cells, MDA-MB134 and BT-474 cells in which both GATA3 and MDM2 were silenced 
showed a significantly higher proportion (10-15%) of apoptotic cells than cells in which 
the two genes were silenced individually, indicating that the dual inhibition was lethal 
for the cells. (Figure 4.9, E). Taken together, our results demonstrate that MDM2 is a 
selected vulnerability in breast cancers with loss of GATA3, independently of the 
HER2 status.   
4.4.3. Synthetic lethality between GATA3 and MDM2 is TP53 dependent 
Given that MDM2 mainly act through the regulation of p53 and mutations in the 
TP53 gene occur in 34% of breast cancers (Figure 4.10), we asked whether the 
synthetic lethal interaction between GATA3 and MDM2 was p53-mediated. We first 
asked if GATA3 mutations and TP53 mutations co-occur in breast cancer. We found 
that in ER-positive breast cancer, both luminal A and luminal B subtypes, GATA3 and 
TP53 mutations are significantly mutually exclusive (q<0.001, in TCGA PanCancer 
Atlas78, MSKCC238, METABRIC66,238, Figure 4.10).  
 
 
Figure 4.10: GATA3 and TP53 mutations are significantly mutually exclusive in breast 
cancers. Oncoprint showing the percentage of breast cancer patients harboring mutations in 
TP53 (34%) and GATA3 (12%). For each patient ER and HER2 status are shown. GATA3 
and TP53 mutations are significantly mutually exclusive (q<0.001). Data are derived from the 
TCGA PanCancer Atlas cohort, the MSKCC Cancer Cell 2018 cohort and the METABRIC 
Nature 2012 & Nat Commun 2016 (>5000 samples).  






Considering the central role of MDM2 protein in the regulation of p53, we 
hypothesized that the synthetic lethal effect observed between GATA3 and MDM2 
may be p53-dependent. To test this hypothesis, we assessed cell growth and 
apoptosis in the ER-positive, GATA3-wild-type, TP53-mutant (p.L194F) T47D breast 
cancer cell line. Contrary to what we observed in TP53-wild-type cells (MCF-7, MDA-
MB134 and BT-474 (mutant but retains transactivation activity)), silencing GATA3 
alone in a TP53-mutant cell context results in a strong reduction of cell viability, 
consistent with the mutual exclusivity of GATA3 and TP53 mutations in patients 
(Figure 4.11-C). Contrary to the results obtained in cells with functional p53, the dual 
GATA3/MDM2 knock-down had no synthetic lethal effect. More strikingly, MDM2 
inhibition was able to partially rescue the effect of GATA3 inhibition (Figure 4.11-C). 
When we assessed apoptosis, we noticed that indeed GATA3 inhibition in the context 
of TP53 mutation was lethal to the cells. We further observed no difference in terms 









Figure 4.11: MDM2 and GATA3 are not synthetic lethal in the TP53-mutant cell line T47D.  
(A) Western blotting showing GATA3 and MDM2 protein level of expression in T47D cells 72 
hours post siRNA transfection. (B) MDM2 and GATA3 mRNA level of expression in T47D cells 
at 24, 48 and 72 hours post siRNA transfection. (C) Effect of MDM2 and/or GATA3 silencing 
on proliferation in GATA3-wild-type, TP53-mutant T47D cell line. (D) Flow cytometry analysis 
of Annexin V and propidium iodide co-staining to measure the percentage of apoptotic cells 
upon MDM2 and GATA3 silencing, alone or in combination, in T47D cells. 
 
If the synthetic lethal interaction between GATA3 and MDM2 is a TP53-dependent 
mechanism, we hypothesized that silencing TP53 expression should partially revert 
the phenotype in TP53-wild type cell lines. Therefore we performed such an 
experiment in the previously used GATA3-mutant MCF-7 cell line where we silenced 
MDM2 alone or in combination with TP53. As expected, TP53 silencing partially 
rescued the synthetic lethal effect induced by MDM2 knock-down (Figure 4.12-C). Of 
note, in the context of GATA3 mutation TP53 knock-down did not display any 
substantial effect on cell viability, in contrast with what we showed in the TP53-mutant 
cell line T47D where loss of function of GATA3 was strongly deleterious for the cells. 
Therefore we speculate that the lethal interaction between loss-of-function GATA3 and 
TP53 mutations is related to the gain-of-function oncogenic properties of TP53 
mutation rather than its loss-of-function, thus suggesting that the mechanism of 
interaction between those two master regulators in breast cancer may be more 
complex than expected. Taken together our results demonstrate that the synthetic 
lethality between GATA3 and MDM2 is dependent on p53. 






FIGURE 4.12: The synthetic lethality between GATA3 and MDM2 is TP53 dependent.  
(A) Western blotting showing p53 and MDM2 protein level of expression in MCF-7 cells 72 
hours post siRNA transfection. (B) TP53 and MDM2 mRNA level of expression in MCF-7 cells 
at 48 hours post siRNA transfection. (C) Effect of MDM2 and/or TP53 silencing on proliferation 
in GATA3-mutant MCF-7 cell line. (D) Flow cytometry analysis of Annexin V and propidium 
iodide co-staining to measure the percentage of apoptotic cells upon MDM2 and TP53 
silencing, alone or in combination, in MCF-7 cells. 
 
4.4.4. GATA3 expression determines response to MDM2 inhibitor in vitro 
The selected vulnerability of MDM2 in GATA3-deficient, TP53-wild-type (GATA3 
and TP53 somatic mutations are mutually exclusive) breast cancers presents MDM2 
as an attractive therapeutic target in this group of breast cancer patients. To test 
whether the apoptotic effects of MDM2 inhibition could be achieved using an MDM2 
antagonist that blocks the interaction between MDM2 and p53, thus activating p53, we 
decided to treat breast cancer cell lines with an MDM2 inhibitor. Since, as mentioned 
in the introduction, idasanutlin (RG7388) is the only molecule that has so far reached 
Phase III in clinical trials, we decided to treat cells with this inhibitor. First of all, we 
assessed the IC50 concentration of idasanutlin for the GATA3-mutant MCF-7 cell line 





(IC50=17.4 μM; Figure 4.13, A). When then treated the GATA3-mutant MCF-7 cells 
with two doses of idasanutlin, the increasing dosage of idasanutlin correlated with 
progressive reduced cell growth and increased apoptosis (Figure 4.13 B,C).  
 
FIGURE 4.13: GATA3-mutant MCF-7 cells respond to Idasanutlin (RG7388) treatment.  
(A) log-dose vs response curve for RG7388 in MCF-7 cells (IC50=17.4 μM). (B) Effect of 
increasing dosage of RG7388 (12.5 and 25 M) on proliferation in GATA3-mutant MCF-7 cell 
line. (C) Flow cytometry analysis of Annexin V and propidium iodide co-staining to measure 
the percentage of apoptotic cells upon increasing dosage of RG7388 in MCF-7 cells. (D) 
Western blotting showing MDM2, p53, GATA3 and pro- (BAX, cl.PARP, p53) and anti-
apoptotic (BCL2) proteins level of expression at 6, 12 and 24 hours post-treatment with DMSO 
(vehicle), RG7388 12.5 μM and RG7388 25 μM. Quantification is relative to the loading control 
(actin) and normalized to the DMSO control for each time point.  
 
p53 and MDM2 regulate each other in a complex negative feedback loop where 
p53 is able to induce MDM2 transcription. MDM2, on the other hand, normally 
quenches the transcription activity of p53. Therefore, as previously reported, the use 





of MDM2 inhibitors usually induces an early upregulation of p53 protein levels, MDM2 
mRNA and protein upregulation together with the up- and down-regulation of pro- and 
anti-apoptotic proteins, respectively239. To assess if idasanutlin was inducing the 
apoptotic cascade according to the classical pathway, we assessed the expression of 
p53, BAX and Bcl-2 by Western blotting at 6, 12 and 24 hours post treatment, together 
with the canonical markers of apoptosis PARP and cleaved PARP (Figure 4.13, D). 
Interestingly, GATA3 levels, both the wild-type and mutant isoforms, decreased after 
treatment with idasanutlin. 
In order to address if the effect of the MDM2 inhibitors on the GATA3 expression 
levels was p53 dependent, and if the effect was due to altered p53 protein stability or 
transcriptional regulation, we again silenced TP53 in MCF-7 cells and treated them 
with 12.5 and 25 μM of RG7388. We observed that when TP53 was silenced, the effect 
of MDM2 inhibitors on both proliferation and apoptosis were partially rescued (Figure 
4.14, A and B), as expected considering that this inhibitor essentially displaces MDM2 
from the binding pocket of p53. Consistent with our previous results, when assessing 
the expression level of GATA3 protein, we again detected its reduction upon treatment 
and we additionally noticed that GATA3 protein expression was higher in the TP53-
silenced cells, where the effect of RG7388 was partially lost (Figure 4.14, C), thus 
suggesting that p53 may be involved in the regulation of GATA3. Then, in order to 
discriminate if the effect of MDM2 inhibitors and of p53 was at the protein or mRNA 
level we assessed GATA3 mRNA level of expression. We showed that GATA3 mRNA 
levels decreased upon treatment with MDM2 inhibitors and increased upon TP53 
silencing (Figure 4.14, D), thus suggesting that p53 may be involved in the 
transcriptional silencing of GATA3. As expected the known p53 targets BAX, BAK and 
MDM2, were upregulated upon treatment with RG7388, while this induction was 
partially rescued by TP53 silencing. The still visible induction of p53 targets in the 
presence of TP53 silencing may be explained by the higher stability of the p53 protein 
upon treatment with MDM2 inhibitor. BCL2, a gene encoding an anti-apoptotic protein 
usually counteracting the actions of the pro-apoptotic targets of p53, was indeed 
downregulated upon RG7388 treatment only in the presence of high levels of TP53. 
Of note, TP53 mRNA was also down-regulated upon treatment, and the effect is 
explained by the complex regulatory feedback loop between MDM2 and p53, where 





MDM2 expression is induced by the treatment with MDM2 inhibitors and is able to 
repress TP53 transcription, in accordance to the model previously described in the 
introduction (Figure 4.6).  
 
 
FIGURE 4.14: Efficient response to RG7388 is dependent on TP53 expression in MCF-
7. (A) Effect of TP53 silencing on proliferation in GATA3-mutant MCF-7 cell line treated with 
12.5 μM RG7388. (B) Flow cytometry analysis of Annexin V and propidium iodide co-staining 
to measure the percentage of apoptotic cells upon TP53 silencing and RG7388 treatment in 
MCF-7 cells. (C) Western blotting showing MDM2, p53 and GATA3 protein levels of 
expression in MCF-7 cells after 12 hours treatment with RG7388 12.5 or 25 μM. Cells were 
treated 24 hours post transfection with siRNA against TP53 or siRNA control. (D) GATA3, 
MDM2, TP53, BAX, BAK and BCL2 mRNA level of expression in MCF-7 cells transfected with 
siRNA control or TP53 siRNA after 12 and 24 hours treatment with 12.5 and 25 μM of RG7388.   
 
We then asked if GATA3 expression levels were able to modulate response to 
idasanutlin. To do so we moved to the GATA3-wild-type cell line models MDA-MB134 
and BT-474 and we compared response to the drug between cells transfected with 





siRNA against GATA3 and cells transfected with non-targeting siRNA control. In both 
cell line models control cells showed poor response to idasanutlin and continued to 
grow under idasanutlin treatment. By contrast, concurrent GATA3 silencing and 
idasanutlin treatment significantly reduced cell proliferation (Figure 4.15, A and C). 
Flow cytometry further demonstrated that the simultaneous silencing of GATA3 and 
idasanutlin treatment induced apoptosis in both cell lines (Figure 9.3, B, D). Taken 
together, our in vitro results support that GATA3 expression levels can modulate 
response to the MDM2 inhibitor idasanutlin (RG7388) in ER-positive breast cancer cell 
lines.  
 
FIGURE 4.15: GATA3-mutant MCF-7 cells respond to Idasanutlin (RG7388) treatment.  
(A) Effect of GATA3 knock-down on proliferation upon treatment with RG7388 12.5 μM in 
MDA-MB134 cells. (B) Flow cytometry analysis of Annexin V and propidium iodide co-staining 
to measure the percentage of apoptotic cells upon GATA3 silencing and RG7388 treatment 
in MDA-MB134 cells. (C) Effect of GATA3 knock-down on proliferation upon treatment with 
RG7388 12.5 μM in BT-474 cells. (D) Flow cytometry analysis of Annexin V and propidium 





iodide co-staining to measure the percentage of apoptotic cells upon GATA3 silencing and 
RG7388 treatment in BT-474 cells. 
 
4.4.5. GATA3 expression determines response to MDM2 inhibitor in vivo 
We then asked whether GATA3 expression levels were also able to modulate 
response to idasanutlin in vivo. In order to do so, we xeno-transplanted the control or 
GATA3-silenced cell lines into zebrafish embryos. In recent years, the zebrafish has 
become a time and cost-effective alternative to mammals240. Indeed, several studies 
have shown engraftment of a diverse range of human tumor cell lines into zebrafish232, 
including breast cancer cell lines241. Additionally, experiments exposing human cancer 
xenografts to anticancer therapies in zebrafish have shown that zebrafish xenografts 
recapitulate response in mammal models242. Successful engraftment in zebrafish can 
be achieved with fewer cells and host numbers can be scaled up easily, improving the 
validity of statistical analyses. Moreover, zebrafish larvae are transparent, allowing the 
direct imaging of cancer progression243 and the readout of the experiments is usually 
very fast (hours to days). This last advantage of the zebrafish model allowed us to use 
the siRNA approach in vivo and to mimic the same conditions previously used in our 
cell line models. The schematic representation of our in vivo experiments is shown in 
Figure 4.16 (panel A).  In detail, we transfected BT-474 cell lines with siRNA against 
GATA3 or siRNA control, as previously described for in vitro studies. We waited 48 
hours post siRNA transfection and we then treated the cells with idasanutlin (25 μM). 
After 24 hours post-treatment we harvested the cells, we labelled them with a red 
fluorescent cell tracker and we injected them into the yolk of zebrafish embryos 
(Figure 4.16-A). 3 days post injection we screened embryos for tumor cell 
engraftment. In general, fish injected with GATA3-silenced BT-474 cell lines pre-
treated with idasanutlin showed fewer and smaller tumors compared with fish injected 
with control cells pre-treated. In many GATA3-silenced injected fish treated with 
idasanutlin we only saw few positive red cells in the yolk, but no tumor formation and 
the tumors formed tended to be smaller than the control counterparts (Figure 4.16-B). 
When assessing the number of tumor-bearing fish we noticed that fish injected with 
GATA3-silenced cells tended to form more tumors compared to control cells (60.4% 
vs 55.3%), in accordance with our results in vitro and the onco-suppressor role of 





GATA3 (Figure 4.16-C, upper panel). However, this difference was not statistical 
significant. Therefore, we compared the number of tumor-bearing fish between the two 
treated groups, control and GATA3-silenced. Of note, fish injected with GATA3-
silenced cells further pre-treated with idasanutlin developed significantly fewer tumors 
compared to fish injected with control cells (Figure 4.16-C, lower panel). In particular, 
when injected with control cells pre-treated with idasanutlin, 64.7% of fish developed 
tumors, while upon GATA3 silencing this number lowered to 43.3%. In addition, we 
also quantified the percentage of tumor cells present in the fish by FACS analysis. In 
the fish injected with the GATA3-silenced cells the percentage of tumor cells relative 
to the total number of cells which were still detectable upon treatment was significantly 
lower than in the fish injected with control cells (Figure 4.16-C-D), thus indicating that 
upon treatment the GATA3-silenced cells were proliferating less in vivo compared to 
the control cells.  
Taken together, our in vivo data confirm and strengthen our in vitro results  and 
strongly suggest that MDM2 is a potential therapeutic target for GATA3-deficient 






















FIGURE 4.16 (A) Schematic illustration of the zebrafish xenotransplantation procedure and 
assay. (B) Representative confocal images of BT-474-induced tumor formation and RG7388 
inhibitor effect. Note that DMSO pre-treated control or GATA3-silenced BT-474 cells (red) 
grew out to form a solid tumor mass, whereas only dispersed BT-474 cells persisted in the 
yolk sac of RG7388-treated fish upon GATA3 silencing. Scale bar: 500 μm. (C) Shown are 
percentages of fish with tumors upon transplantation with GATA3-silenced versus control BT-
474 cells pre-treated with DMSO (upper panel) or GATA3-silenced versus control BT-474 cells 
pre-treated with RG7388. More than 100 embryos were analyzed per group in two 
independent experiments. Statistical significance was calculated using the Fisher’s exact test. 
(D) FACS analysis showing the percentage of red-tracker labelled tumor cells extracted from 
the embryos. Bars represent three independent replicates. Each replicate is a whole cell lysate 
of 7 different fishes. Statistical comparison was performed by non-parametric t-test.  
  






4.5.1. GATA3 loss-of-function mutations and/or GATA3 loss of expression as a 
new synthetic vulnerability responsive to MDM2 inhibition in ER-positive breast 
cancer 
Over the past 25 years, advances in genome sequencing have led to a paradigm 
shift in cancer treatment. In fact, in the so called “post-genomic era” it is now possible 
to identify somatic genetic and epigenetic changes in tumors. Efforts to understand 
the underlying cell-autonomous, genetic drivers of tumorigenesis have enabled the 
development of clinically relevant targeting agents. Building on the concept of tumor 
cell vulnerability, precision oncology has the advantage of providing individualized, 
highly tumor-cell specific therapies with fewer adverse effects compared to the 
standard of care based on chemotherapeutic agents244,245. The main idea behind the 
new era of cancer therapeutics is to target weaknesses or dependencies present in 
the tumor cells which are absent, or at least less pronounced, in normal cells. So far, 
the vast majority of genotype-targeted cancer therapy has been based on the 
phenomenon of “oncogene addiction”, the specific and common situation in which a 
cancer cell has to fully rely on the activation of an oncogene or of an oncogenic 
pathway in order to survive. In fact, loss-of-function mutations in tumor suppressor 
genes are more difficult to target, as it is not yet possible to restore the function of 
mutated or deleted genes132. However, although small-molecule and antibody-based 
inhibitors have been proven highly effective for some tumour genotypes, not all 
tumours have targetable gain-of-function oncogenic alterations. Moreover, cancer 
cells are able to activate and rely on secondary oncogenic pathways and therefore 
escape mechanisms of death. The induction of therapeutic resistance and the lack of 
druggable oncogenes in some tumors have led to the development of a secondary 
approach, which consists in taking advantage of tumor-specific synthetic lethal 
interactions135. With this approach it is then possible to leverage both oncogenic and 
non-oncogenic mutations by identifying second-site targets that, when disrupted in 
conjunction with a tumor-specific mutation, results in synthetic lethality. Large-scale 
deep RNAi153,154 and CRISPR–Cas9155 screens coupled with computational 
approaches158,159 have emerged as a powerful tool to infer such genetic interactions. 





One of these large pan-cancer screens is the recently published Project DRIVE, based 
on a comprehensive RNAi library targeting ~8000 genes160.  
Using the recently developed SLIdR (Synthetic Lethal Identification in R, 
manuscript under review, see other accomplishments) algorithm on the data derived 
from Project DRIVE160, we identified MDM2 as a selective synthetic lethal interactor of 
GATA3 in ER-positive breast cancer. This newly discovered synthetic lethal pair is of 
particular interest considering that GATA3 mutations occur in 15% of primary and 18% 
of metastatic ER-positive breast cancers246–248, thus making it an attractive candidate 
for targeted therapy. Moreover, in breast cancer GATA3 level of expression also 
correlates with poor outcome and responsiveness to therapy. In particular, low levels 
of GATA3 are indicative of poor prognosis and more aggressive cancers, 
characterized by larger tumor size, higher histological grades and enhanced 
metastatic potential118,122,249. In fact, GATA3 expression is lost as luminal cells de-
differentiate and is well known that it suppresses epithelial-to-mesenchymal 
transition119,120,122. Unfortunately, two main characteristics of GATA3 does not allow 
the development of any specific treatment: first of all transcription factors are usually 
not considered druggable candidates because of their nuclear localization and 
absence of a well-defined drug binding site; second, GATA3 mutations are mainly 
trucating, therefore loss-of-function mutations. Our discovery of MDM2 as a selective 
synthetic lethal partner of GATA3 will overcome the challenge of targeting loss-of-
function mutations in GATA3 and/or GATA3 loss of expression in GATA3-deficient 
tumors and will provide a specific and tailored treatment for a subclass of patients 
associated with a worse prognosis and relapse. 
In particular, we have shown that inhibition of MDM2, both through a siRNA 
approach or by using the MDM2 inhibitor Idasanutlin (RG7388), is able to hamper cell 
proliferation and to induce apoptosis in ER-positive breast cancer cell lines harboring 
the same truncating GATA3 mutations as those commonly found in patients. 
Furthermore, we have shown that dual inhibition of GATA3 and MDM2 in the context 
of a GATA3 wild-type protein also reduces proliferation and induces cell death. We 
obtained the same phenotype with both luminal A and luminal B cell lines, thus 
suggesting that this synthetic lethal interaction is not restricted to any ER-positive 
subtype. In order to prove that alteration of GATA3 expression is able to modulate 





response to MDM2 inhibitors, we combined GATA3 silencing and idasanutlin 
treatment in ER-positive breast cancer cell lines and we demonstrated that GATA3 
loss of expression sensitizes cells to idasanutlin treatment. This discovery broadens 
the use of MDM2 inhibitors not only for breast cancer patients harboring GATA3 loss-
of-function mutations, but also for those who have loss of GATA3 expression, thus 
having very significant clinical implications.  
Our data are even more relevant by the fact that selective small molecules 
directed against MDM2 are not only readily available, but already in Phase III clinical 
trials. Of note, by identifying a molecular biomarker (i.e. the loss of or low GATA3 
expression) predictive of response to MDM2 inhibitors, we speculate that our findings 
may contribute to a better patient stratification in the design of clinical trials aimed to 
evaluate the efficacy of MDM2 inhibitors in solid tumors and, more specifically, in 
breast cancer. 
4.5.2. GATA3 and MDM2 synthetic lethal interaction is p53 dependent: 
speculations about the restoration of p53 function as an appealing strategy for 
anticancer therapy in breast tumors 
MDM2 is involved in the negative regulation of p53250 and itself serves as an 
oncogene, reported to be overexpressed in several cancer types165,170,172–175,. Several 
small-molecule inhibitors of the MDM2-p53 interaction have been used or are being 
tested in cancer types in which MDM2 is commonly found amplified214 and the use of 
MDM2 inhibitors is therefore restricted to a TP53 wild-type tumor context. Although 
mutations in the tumor suppressor TP53 gene are thought to be the most abundant 
genetic alterations occurring in cancers, the relative prevalence of TP53 mutations in 
ER-positive breast cancer is low (luminal A 12% and luminal B 29%) compared to 
HER2-enriched or triple negative molecular subtypes (~80%), and total MDM2/4 
alterations are about 12%78,250. Moreover, increased MDM2 expression in breast 
cancer tissue is associated with poor prognosis78,251, making those cancers suitable 
candidates for treatment with MDM2 inhibitors. Considering the central role of MDM2 
protein in p53 regulation, we hypothesized that the synthetic lethal effect observed 
between GATA3 and MDM2 may be p53-dependent. Indeed, we showed that silencing 
of TP53 in the GATA3-mutant cell line MCF-7 is able to rescue the synthetic lethal 
interaction between MDM2 and GATA3. Additionally, we noticed that silencing of 





GATA3 in the context of a TP53-mutation was deleterious for the cells. Taking 
advantage of the publicly available data of the TCGA PanCancer Atlas, the MSKCC 
Cancer cell and the METABRIC cohorts (5511 patients samples), we showed that 
GATA3 and TP53 mutations are indeed significantly mutually exclusive (q<0.001) in 
breast cancer patients. Therefore our cell lines models resemble what is observed in 
patients and suggest that GATA3 and TP53 may be involved in the same 
transcriptional network. Many data in literature actually already support this theory. 
p53, for instance, has been shown to play a role in luminal differentiation, as it restricts 
luminal progenitors cell amplification252. Moreover, it has been reported that ERα is 
able to repress p53-mediated transcriptional activation and prevent p53-dependent 
apoptosis253–255. GATA3 is necessary for the ERα functional signature. In particular, 
GATA3 binding to cis-regulatory elements located within the ESR1 gene is required 
for RNA polymerase II recruitment to its promoters256. Additionally, clinical findings 
also indicate that the presence of wild-type p53 correlates with a positive therapeutic 
response to the endocrine agent tamoxifen 253–255. Taken together these data 
strengthen our findings and strongly suggest that disruption of this ERα-p53 interaction 
and the restoration of p53 function might be an appealing strategy for anticancer 
therapy in breast tumors257.  
4.5.3. MDM2 inhibitors as an alternative therapeutic option for ER-positive 
breast cancers resistant to hormonal therapy 
Estrogen receptor is expressed in 70-80% of all breast carcinomas76, therefore 
endocrine therapy based on selective modulators of the estrogen receptor, such as 
tamoxifen or fulvestrant, is currently the standard of care for patients diagnosed with 
ER-positive breast cancer. However, as often happens with many targeted-specific 
therapies, 30-50% of early breast cancer patients develop resistance to endocrine 
therapy81,82, indicating that additional therapeutic options for these patients are 
urgently needed. By proposing a new potential treatment for a specific subclass of ER-
positive breast cancer, our data may also provide an alternative for these patients. In 
support of this, prior studies have characterized a connection between estrogen 
receptor and MDM2 expression in breast cancer. Indeed, MDM2 gene amplification in 
breast cancer is observed only in estrogen receptor (ER)-positive tumors187,258,259 and 
MDM2 expression positively correlates with ERα expression in primary human breast 





tumors and human breast cancer cell lines206,210,260–262. Additionally, it has been shown 
that MDM2 overexpression enhances ERα-mediating gene expression and estrogen 
responsiveness through direct interactions with ERα197,260 and through a complex 
negative feedback loop206,260. This builds upon the complex regulatory loops that have 
previously been described for p53 and ERα and point to the existence of important 
signaling crosstalk amongst ERα, MDM2 and p53 in human breast cancer.  
As mentioned before, GATA3 expression is also strongly associated with ERα 
expression in breast cancer, and it is now well accepted that GATA3 acts as a pioneer 
factor that recruits ERα during the luminal differentiation of the mammary gland. 
Strikingly, failure to respond to hormonal therapy and poor prognosis are also 
associated with a lack of GATA3 expression125, underlying how important this factor is 
for the ERα transcriptional machinery and therefore essential for an efficient anti-
tumoral effect mediated by hormonal therapy. Acting downstream of estrogen 
receptor, whose mutations and genomic rearrangements account for endocrine 
therapy resistance, we speculate that the GATA3 and MDM2 synthetic lethal 
interaction may be able to bypass the constitutive activation of ESR1. Therefore we 
suggest that MDM2 inhibition may also represent an alternative therapeutic strategy 
for ER-positive breast cancer patients who have developed endocrine resistance, a 
hypothesis which requires further testing. In particular, we intend to use MCF-7 cells 
harboring constitutively active ESR1 mutations (D538G and Y537G), and therefore 
resistant to hormonal therapy, to test the efficacy of idasanutlin treatment as an 
alternative therapeutic strategy (experiments in progress, data not shown). Further, 
we plan to couple MDM2 inhibitors and endocrine therapy in order to test their potential 
synergistic effects.  
4.5.4. Concluding remarks 
With the present work, we have shown for the first time that the MDM2 and GATA3 
genes are synthetic lethal interactors in estrogen receptor-positive (ER-positive) 
breast cancer. Specifically, our data strongly suggest that MDM2 inhibition might be 
useful for the treatment of ER-positive breast cancer patients harboring loss of function 
mutations and/or loss of expression of the GATA3 mRNA/protein.  
With two independent experiments performed in a zebrafish xenograft model we 
have shown a significant and consistent trend of reduced tumorigenicity in GATA3-





silenced cells pre-treated in wells with idasanutlin. However, the impossibility to 
directly treat the fish with idasanutlin given its toxicity convinced us to use a second 
model. In particular, we are going to inject breast cancer cells after siRNA transfection 
into chicken embryos and directly treat the formed tumors with idasanutlin (experiment 
in progress). Last, as mouse xenografts are the most widely accepted preclinical 
model for drug testing, we plan to subcutaneously inject ER-positive breast cancer 
cells with intact or knock-out GATA3 (we are going to use both heterozygous and 
homozygous clones) and assess tumor size after treatment with idasanutlin as 
reported in the literature. We hope that this parallel approach will confirm that GATA3 
level of expression is predictive of response to MDM2 inhibitors treatment in vivo.  
 
The relevance of our findings specifically relates to the high prevalence of GATA3 
loss-of-function mutations or loss of expression in ER-positive breast cancer patients 
and the association of GATA3 loss with poor prognosis and occurrence of resistance 
to endocrine therapy. Additionally, it also pertains to the existence of already clinically 
available drugs targeting the MDM2-p53 interaction, such as the small molecule 
inhibitor idasanutlin, which makes our findings directly translatable into the clinic thus 
providing a concrete and accessible alternative therapeutic option for a specific 











5. Project 2: HOXA13 overexpression drives hepatocyte proliferation 
and liver tumorigenesis in mice 
5.1.Introduction 
5.1.1. Epidemiology of Hepatocellular-carcinoma 
Liver cancer is a global health problem: with an incidence of 841,080 new cases 
in 2018 it is the sixth most commonly diagnosed cancer and the fourth leading cause 
of cancer death worldwide21 (Figure 5.1-A). In most world regions the rates of both 
incidence and mortality are two to three times higher among men, thus liver cancer 
ranks fifth in terms of global cases and second in terms of deaths for males (Figure 
5.1-B-C). The highest rates are observed in Eastern and South-Eastern Asia and in 
Northern and Western Africa. (Figure 5.1-C) 
 
FIGURE 5.1. Pie charts present the distribution of incidence and deaths for the 10 most 
common cancers in 2018 for (A) both sexes and (B) only males. The area of the pie charts 
reflects the proportion of the total number of cases or deaths; non-melanoma skin cancers are 
included in the “other” category. (C) Bar chart of region-specific incidence and mortality age-
standardized rates for cancers of the liver in 2018. Rates are shown in descending order of 
the world (W) age-standardized rate. Source: GLOBOCAN 2018. 
Liver cancer comprises diverse, histologically distinct primary hepatic neoplasms, 
which include hepatocellular carcinoma (HCC), intrahepatic  bile duct carcinoma 
(cholangiocarcinoma), hepatoblastoma, bile duct cystadenocarcinoma and others263. 





Among all primary liver cancers, HCC is the most common neoplasm, accounting for 
approximately 75%-85% of all cases, the remaining cases account for intrahepatic 
cholangiocarcinoma (10%-15%) as well as other rare types21.  
5.1.2. Etiology and risk factors  
In contrast to other human cancers, risk factors for HCC development are well 
established. Indeed, HCC is very common in patients with chronic liver disease, 
characterized by the progressive development of fibrosis and cirrhosis due to 
damaging agents such as viral infection or alcohol intake. Specifically, the main risk 
factors for HCC are chronic infection with hepatitis B virus (HBV) or hepatitis C virus 
(HCV), aflatoxin-contaminated foods, heavy alcohol intake, obesity, and type 2 
diabetes36. These factors at least partially explain the uneven geographical distribution 
of this malignancy worldwide. In fact, the global incidence of HCC almost parallels that 
of chronic HBV infection, with the highest rates of HCC incidence in Asia and Sub-
Saharan Africa where HBV infection is highly prevalent (Figure 5.2). In Africa aflatoxin 
B1 has also been shown to act synergistically with HBV in causing liver cancer thus 
explaining the early onset of the tumor in these countries264. HCV infection, instead, is 
one of the leading causes of HCC in North America and Europe, followed by alcohol 
abuse. Emerging causes of HCC are metabolic syndromes characterized by obesity 
and type 2 diabetes. The hepatic consequence of the metabolic syndrome is the non-
alcoholic fatty liver disease (NAFLD), estimated to affect up to one-third of the adult 
population in several developed as well as developing countries265.   






FIGURE 5.2. Age-standardized global incidence of HCC. Figure obtained from Llovet et al.264 
 
Hepatitis B virus. 5 to 10% of HBV infected patients develop chronic hepatitis B 
infection which accounts for 54% of all HCC cases worldwide, thus being the major 
risk factor for the development of this tumor worldwide264.  HBV can drive HCC 
development directly or indirectly. Direct mechanisms include insertional 
mutagenesis266 and/or alterations of cellular pathways by HBV-encoded proteins267. 
Indirect mechanisms of HBV-induced HCC pathogenesis are generally immune 
mediated. HBV-infected cells induce an immune response which results in hepatocyte 
death and inflammation in the surrounding tissue268. Persistent inflammation caused 
by the chronicity of HBV infection can then lead to cirrhosis and accumulation of 
oncogenic mutations thus leading to HCC development267.   
Hepatitis C virus. HCV is the second most frequent risk factor of HCC, accounting 
for 31% of all cases264. Compared to HBV and its progression to chronic hepatitis B, 
HCV results in chronic infection in a much larger proportion of infected individuals, with 
60%–80% of all patients developing chronic disease267. The pathogenesis of HCCs 
associated with HCV is also based on direct and indirect mechanisms, similar to that 
driven by HBV267,268.  





Alcoholic liver disease. As mentioned, alcohol abuse over a prolonged period of 
time is one of the main risk factors for HCC development. With uneven distribution 
among different areas, 10% to 20% of total HCCs can be attributed to the heavy use 
of alcohol and its liver consequences269. However, only 35% of heavy drinkers will 
eventually display a severe disease comprising fibrosis and cirrhosis269,270. Alcohol 
dehydrogenase (ADH) enzyme and Cytochrome P450 2E1 (CYP2E1) are highly 
expressed in hepatocytes, which are the main cells responsible for ethanol 
detoxification. Ethanol metabolism generates byproducts that alter the intracellular 
redox potential and favors the generation of fatty acids, thus leading to alcoholic 
steatosis271. As for chronic viral infection, this ultimately leads to persistent inflamed 
tissue which may progress to fibrosis, cirrhosis and eventually to HCC.  
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis 
(NASH). NAFLD is an emerging cause of HCC development related to obesity, 
diabetes, and metabolic syndromes. Patients affected by NAFLD present an increased 
fat accumulation in hepatocytes that can progress to hepatitis265,272. NAFLD can 
progress from simple steatosis to NASH and cirrhosis, ultimately causing HCC265.  
However, several groups have shown that up to ~50% of patients with NAFLD or 
NASH do not have a background of cirrhosis272,273, thus refuting the general rule 
according to which HCC is generally associated with advanced fibrosis or 
cirrhosis.The pathophysiology of the progression from NAFLD to NASH, cirrhosis and 
eventually HCC is a result of tissue inflammation and oxidative stress mediated by 
lipid accumulation265. For NAFLD patients that progress to HCC without cirrhosis 
development, the pathophysiologic mechanisms are less clear but likewise involve 
insulin resistance associated with oxidative stress and inflammation274.  
Aflatoxin B1. Inappropriate food storage is one of the main causes of fungal growth 
and contamination by toxin contamination. Aflatoxin B1 (AFB1), in particular, is 
produced by two fungal species, Aspergillus flavus and Aspergillus parasiticus275.  
Most HCC cases associated with AFB1 can be found in sub-Saharan Africa and south-
east Asia, because of local climate conditions which favor the growth of fungal 
species276. In those regions, and especially in Sudan, AFB1 is a frequent cofactor in 
HBV-induced HCCs264, as previously mentioned. AFB1 is carcinogenic mainly 
because of its ability to produce DNA adducts and induce DNA damage. Additionally, 





the specific liver toxicity is also partially due to the conversion of AFB1 into a reactive 
compound by the Cytochrome P45276.  The  R249S substitution in the TP53 gene is 
the most common mutation associated with AFB1 intoxication276. 
5.1.3. Prevention, diagnosis, and treatment of HCCs  
Prevention. HCC is one of those cancers for which prevention is actually possible. 
As already mentioned, HCC is very common in patients with chronic liver disease, 
therefore the most effective way to prevent it is actually to prevent all the above 
mentioned risks factor that lead to chronic liver injury. The best example of this is HBV 
vaccination, which has already been demonstrated to reduce HCC incidence277. 
Similarly, treatment and eradication of HCV results in a decreased HCC incidence278, 
however, when patients have already progressed to cirrhosis before virus eradication, 
the risk to develop HCC seems to remain278,279. Same is true for alcohol intake: primary 
prevention consisting in counselling against alcohol abuse would reduce the incidence 
of alcohol-associated cirrhosis and the consequent risk of HCC. Promoting a healthy 
lifestyle may also contribute to reduce the risk to develop diabetes and NAFLD. Thus, 
in summary, prevention of HCC largely depends on prevention or treatment of the 
underlying liver disease. 
Diagnosis. The human liver is one organ in our body that better compensates 
damage and impairment. Unfortunately, this means that HCC onset is most of the time 
occurring without any symptoms until the very late stage. Therefore, patients usually 
die within a few months after diagnosis making HCC one of the most aggressive and 
lethal cancers in humans. However, HCC has actually a prolonged subclinical course 
which may provide several opportunities for early detection, and early-stage HCC 
lesions are usually very small and treatable with non-invasive methods. These have 
led to the development of protocols for the surveillance of HCC development in 
patients with chronic liver disease. In general, the American- and European 
Associations for the Study of the Liver (AASLD and EASL, respectively) both 
recommend the surveillance of patients with cirrhosis, due to any cause, because 
previous studies clearly demonstrated improved survival rates280,281. HBV or HCV 
infections associated with advanced fibrosis, or HBV infection patients without 
cirrhosis but occurring in specific ethnic groups, are also criteria for being included in 





the surveillance program280,281. Surveillance protocols consist of ultrasound alone or 
in combination with biomarkers measurements. However, the use of biomarkers 
remains controversial since many of them are more frequently associated with 
advanced-stage disease than early-stage. However, among them alpha-fetoprotein 
(AFP), whose expression normally restricts to the fetal developmental stage,  is the 
most commonly used in practice280,281. Patients who are enrolled in a surveillance 
program are generally asymptomatic and with early-stage HCC lesions. Conversely, 
patients diagnosed outside surveillance usually present advanced stage lesions with 
or without portal vein invasion. Usually these patients show advanced liver dysfunction 
with many symptoms including malaise, weight loss, anorexia and abdominal 
discomfort. All patients are diagnosed by identification of a new liver nodule on 
abdominal ultrasound, and diagnostic confirmation comes through non-invasive 
criteria or with a biopsy. Non-invasive radiological imaging, such as contrast-enhanced 
computer tomography or magnetic resonance imaging, can be highly informative in 
patients with cirrhosis280,281 because of the dual blood supply of the liver and the 
particular vascular profile of HCCs. In fact, while the majority of the blood enters the 
liver through the portal vein, HCCs are predominantly vascularized through neo-
angiogenesis from the hepatic artery cells282. This feature can be used to specifically 
recognize an HCC nodule due to its dense contrast enhancement in the arterial phase 
and a decreased signal in the portal venous phase282. However, not every HCC nodule 
can be diagnosed with this procedure. In such cases, especially in non-cirrhotic 
patients, tumor biopsies represent the diagnostic standard. In general, investigation of 
lesions follows these recommendations: for nodules <1 cm in size, ultrasound with 
follow-up at 4 months; for lesions of 1-2 cm diagnosis should be based on non-invasive 
criteria or biopsy-proven pathological confirmation. A second biopsy is recommended 
in case of inconclusive findings, or growth or change in enhancement pattern identified 
during follow-up; for lesions >2 cm, the radiological hallmarks of HCC define diagnosis; 
if the radiology is not typical in at least one of two imaging techniques (CT and MRI), 
a liver biopsy is recommended280,281. 
Pathological diagnosis of HCC is based on the definitions of the International 
Consensus Group for Hepatocellular Neoplasia283 and is recommended for all nodules 
occurring in non-cirrhotic livers, and for those cases with inconclusive or atypical 





imaging appearance in cirrhotic livers. The sensitivity of liver biopsy depends on 
several factors such as location, size and expertise, and ranges between 70% and 
90%. Pathological diagnosis is particularly complex for nodules between 1 and 2 cm, 
thus tissue markers might help to provide a more standardized diagnosis of these 
tumors. Genomic, transcriptomic, proteomic and immunostaining studies have been 
used in order to identify markers for early detection of HCC. Some of the markers 
identified by genomic studies have been prospectively assessed by 
immunohistochemistry and among them, a promising marker is Glypican 3 (GPC3), 
Heat Shock Protein 70 (HSP70) and Glutamine Synthetase (GS) have so far shown 
the best specificity and sensitivity alone or in combination284. The International 
Consensus Group of Hepatocellular Neoplasia has adopted the recommendation to 
define a pathological diagnosis of HCC if at least two of these markers are positive283.  
Additional staining can be considered to assess neo-vascularisation (CD34) or 
potential progenitor cell origin (keratin 19, EpCAM)285. In particular, keratin 19 (K19), 
a progenitor cell/biliary marker has been shown to correlate with poor prognosis. 
Moreover, K19 recognizes biliary features in mixed forms of HCC/cholangiocarcinoma, 
which are not always detected on hematoxylin–eosin stain284,286. 
Treatment. After a confirmed diagnosis of an HCC, tumors are staged according 
to the Barcelona Clinic Liver Cancer (BCLC) classification (Figure 5.3). The BCLC 
staging system provides doctors with an evidence-based algorithm that links tumor 
stages with treatment allocation policies280,281,287,. In particular, this system looks at the 
number and size of tumors in the liver, the general performance of the patient 
(performance status - PS), as well as the liver function. HCC patients can be stratified 
into five different groups according to their disease stage: BCLC 0; A; B; C; and D287. 
Treatments are classified as radical therapies, with the potential to cure HCC, or 
palliative therapies, which are aimed at extending survival rates and improving quality 
of life. Radical therapies include surgical resection, liver transplantation or 
percutaneous ablation, whereas palliative therapies include chemo-embolization and 
sorafenib280,281.  Treatment modalities differ according to the disease stage. Very 
early- to early-stage disease patients (BCLC 0 and A), can be eligible for potentially 
curative treatments such as surgical resection or liver transplantation (Figure 5.3). 
However, requirements for these treatment options are a well-preserved liver function, 





e.g. no cirrhosis; and the absence of portal hypertension280,281,287,288. Patients with 
early-stage HCCs that don’t meet the criteria for surgery are then usually treated with 
thermal ablation, either with radiofrequency (RFTA) or more recently with 
microwaves288. Intrahepatic recurrence and de novo HCC account for 70% of 5-year 
recurrence after resection289, and no adjuvant therapies are able to prevent this 
complication290. Patients with intermediate-stage disease (BCLC B) are characterized 
by multinodular disease, preserved liver function, and the absence of tumor-related 
symptoms, vascular invasion an extrahepatic spread. Those patients are typically 
treated with transarterial chemoembolization (TACE, Figure 5.3.).  TACE is a minimally 
invasive technique consisting of delivering small beads loaded with a 
chemotherapeutic agent, usually doxorubicin, to restrict tumor blood supply and at the 
same time release the drug locally264,288. An alternative to TACE is the selective 
internal radiation therapy (SIRT), where instead of drug the beads contain beta-
radiation emitting isotopes 264. Patients with advanced-stage disease (BCLC C) are 
usually eligible for systemic targeted therapies (Figure XX)288. Sorafenib (Nexavar®), 
a multikinase inhibitor targeting the RAF/MEK/ERK pathway as well as angiogenesis 
291,292, has been shown to extend survival by 2.8 months in the sorafenib HCC 
Assessment Randomized Protocol (SHARP) trial291. The benefit coming from 
sorafenib treatment is obviously marginal and the efficacy is limited due to side effects 
and the occurrence of drug resistance. Unfortunately, sorafenib is still the main choice 
for the first-line treatment of HCC patients. However, new kinase inhibitors - first-line 
lenvatinib293, and second-line regorafenib, cabozantinib, and ramucirumab293,294 have 
been demonstrated to improve clinical outcome, although the median overall survival 
remains ~1 year. Nivolumab (PD-1 inhibitor) is another second-line option for patients 
who have progressed on sorafenib295. Finally, patients with end-stage disease (BCLC 
D) should be only considered for nutritional and psychological support and proper 
management of pain, but are normally not included in clinical trials. 
 






FIGURE 5.3. The BCLC classification system. Figure obtained from Llovet et al.264 
 
5.1.4. Histopathological features of HCC 
The pathological evaluation of HCC biopsies or surgically-resected tumors 
includes the determination of the differentiation grade; growth pattern; the presence of 
immune cell infiltrates; necrosis; and other important histopathological features that 
can strongly differ between patients, underling the huge heterogeneity of 
hepatocellular carcinoma.  
Precursor lesions.  Typical adenoma-carcinoma sequence does not represent a 
frequent pathway in hepatic carcinogenesis, however rarely hepatocellular adenoma 
(HCA) can act as a precursor lesion296. HCA occurs mainly in female patients using 
oral contraceptives and in male patients with glycogen storage disease or androgen 
treatment. More common precursor lesions are dysplastic foci and nodules. Both 
dysplastic foci and nodules are uniform lesions with morphology, cytoplasmic staining, 
nuclear size and cellular atypia different from the surrounding liver tissue. By definition, 





foci are < 1 mm in size. In contrast, dysplastic nodules are defined as being larger than 
1mm in size. Among the different histological features, dysplastic nodules may display 
increased nuclear/cytoplasmic ratio, nuclear hyperchromasia, irregular nuclear 
borders, peripheral location of the nucleus, occasional mitoses, basophilic cytoplasm 
and pseudo gland formation296. 
Histological grade. The histologic grade describes the degree of abnormality and 
differentiation between tumor and normal cells. The most widely used grading system 
in HCC is the Edmondson and Steiner system297, comprising a four-scale system from 
grade I to IV (Figure 5.4, upper panel). Grade I mainly consists of small tumor cells, 
arranged in trabeculae, with abundant cytoplasm and minimal nuclear irregularity. 
Grade II tumors have prominent nucleoli, hyperchromatism and some degree of 
nuclear irregularity. Grade III HCCs display more pleomorphism in terms of cellular 
size and shape and can have angulated nuclei. Grade IV HCCs have the highest 
degree of cellular variability and in some cases can show the presence of anaplastic 
giant cells296,297.  






FIGURE 5.4. Histological features of hepatocellular carcinoma. Upper panel: A: 
Micrographs displaying the four differentiation grades according to Edmondson and Steiner (I-
IV). Micrographs obtained and adapted from Iavarone et al.87. Lower Panel: (A-D) Growth 
patterns of progressed hepatocellular carcinoma \. A: HCC with solid growth pattern (HE, × 
200); B: HCC with pseudoglandular growth pattern (HE, ×100); C: HCC with trabecular growth 
pattern [hematoxylin and eosin (HE), × 300]; D: HCC with giant cell formation (HE, × 200). (E-
H) Histologic variants of hepatocellular carcinoma. E: clear cell variant (HE, × 100); F: HCC 
with lymphoid stroma (HE, × 100/× 200). G: steatohepatic variant (HE, × 200); H: fibrolamellar 
variant (HE, × 50). 
Growth patterns.  The most common growth patterns of HCC are: solid; 
pseudoglandular or acinar; trabecular; HCC with giant cell formation (Figure 5.4, lower 
panel)296,297.  Histomorphologic appearance of hepatocellular carcinoma varies greatly 
from patient to patient and even in a single patient. Progressed HCCs usually show 
an expansive and infiltrative histologic growth pattern with neo-vascularization and 
possible infiltration. There are no portal tracts seen within the tumor and all the 
classical histologic patterns are usually present. Both early and progressed HCC 
appear hypervascular because of earlier neovascularization with unpaired arteries, not 





associated with a portal tract. In fact, in HCC angioarchitecture plays a very important 
role during tumor growth and, as already mentioned, is also an essential diagnosis 
based on imaging.  
Histologic variants. The clear-cell variant of HCC is usually arranged in a 
trabecular pattern and is characterized by a clear cytoplasm containing glycogen and 
fat vesicles298 (Figure 5.4-E). HCC with lymphoid stroma is only described in a few 
case reports. This tumor consists of a massive inflammatory infiltrate, often with very 
few identifiable tumor cells (Figure 5.4-F)299,300. Steato-hepatic HCC is characterized 
by a steatotic appearance of > 5% of the tumor, presence of Mallory-bodies, fibrosis, 
inflammation and ballooning of the hepatocytes. These patients often suffer from non-
alcoholic steatohepatitis, but this phenotype is also seen in patients without 
steatohepatitis in the non-neoplastic liver tissue299. Fibrolamellar HCC is a rare 
subtype accounting for less than 1% of all tumors301. This subtype is typical in young 
patients without liver cirrhosis and no known predisposing factors and generally has a 
better prognosis than other HCCs301,302.  Histologically it shows tumor cells growth in 
sheets and trabeculae, separated by collagen fibers and may have a central scared 
zone with possible calcification (Figure 5.4-H)301,302.  
5.1.5. Hepatocellular carcinoma pathogenesis  
As previously mentioned, chronic liver disease caused by all the described 
etiological agents is often the pre-condition for the onset of HCCs. Most of the time, 
liver damage culminates in the development of cirrhosis, a process that normally takes 
several years to decades, thus explaining why HCC typically occurs in old patients303. 
More in detail,  the progression from the healthy liver to HCC typically starts with 
hepatocyte injury incurred by one of the etiological agents followed by necrosis and 
hepatocytes compensatory proliferation (Figure 5.5). Persistent liver damage results 
in continuous cycles of this destructive–regenerative process which in the end fosters 
a chronic liver disease condition. This process is accompanied by an increment of 
tissue inflammation mediated by the innate and adaptive immune system.  Years later,  
sustained immune response leads to excessive collagen deposition which, coupled 
with the reduced regenerative potential of the hepatocytes, eventually results in 
progression from fibrotic scars to complete cirrhosis. Cirrhosis is characterized by 





abnormal liver nodule formation surrounded by collagen deposition and scarring of the 
liver, leading to hyperplastic nodules first, followed by dysplastic nodules. Dysplastic 
nodules accumulate somatic mutations and epigenetic modifications in driver and 
passenger genes and ultimately  develop in HCC,  in a stepwise sequence303. 
FIGURE 5.5. Pathogenesis of HCC development. Chronic hepatocyte damage results in 
compensatory proliferation and tissue scarring followed by genetic and epigenetic alterations 
that induce cancer formation. Created with Biorender.com. 
5.1.6. Molecular alterations and drivers of hepatocarcinogenesis 
As mentioned, hepatocarcinogenesis is a complex multistep process normally 
originating in the context of liver cirrhosis. The classical model of HCC progression 
starts with the development of pre-cancerous cirrhotic nodules with low-grade 
dysplasia, called low-grade dysplastic nodules (LGDNs). LGDNs subsequently 
develop into high-grade dysplastic nodules (HGDNs) that can transform into early-
stage HCC (stages 0 and A) and eventually progress into more advanced HCC (stages 
B and C) (Figure 5.6.).  





FIGURE 5.6. Progression of cirrhosis to early-stage HCC. HCC progression starts with the 
development of low-grade dysplastic nodules (LGDNs). LGDNs subsequently develop into 
high-grade dysplastic nodules, that can transform into early-stage HCC. TERT promoter 
mutations occur early during HCC carcinogenesis and are present in >50% of early-stage 
HCCs. Alterations in several pathways and cellular processes (right panel) occur during the 
progression from cirrhotic nodules to HCC. Figure obtained and modified from Llovet et al.264 
As true for many other solid tumors, HCC is also the result of the accumulation of 
several somatic alterations which accumulate during this multistep process. Each HCC 
nodule usually displays a mean number of 40 functional somatic alterations and each 
tumor results from the unique combination of these alterations together with epigenetic 
modifications304,305. These observations have led to the general well accepted opinion 
that HCC is a very complex and heterogeneous disease. However, alterations are not 
randomly accumulated, but several pathways are now well know to cooperate to 
promote oncogenesis and can also be associated to specific risk factors. Among the 
main pathways involved in hepatocytes malignant transformation there are activation 
of the WNT-β-catenin signalling cascade, re-expression of fetal genes, deregulation 
of the protein-folding machinery and response to oxidative stress, and re-expression 
of telomerase. In particular, it is quite broadly accepted now that telomerase 
maintenance plays a major role in the initiation and promotion of neoplastic 
transformation of cirrhotic lesions. Cell mitosis results in progressive shortening of 
telomeres and leads to cell senescence; therefore, immortal cells constitutively 
activate telomerase to maintain telomere length and escape from telomere-induced 
replicative senescence306,307. A recent study clarified that increased expression of 
TERT also promotes immortalization by bypassing oncogene-induced senescence308. 
In humans, TERT is not expressed in normal hepatocytes, but becomes re-expressed 
early during hepatocarcinogenesis in LGDNs and particularly HGDNs309–311. 
According to this model, constitutive expression of Telomerase Reverse Transcriptase 





(TERT) gene (Figure 5.6) enables the unlimited proliferation of cirrhotic hepatocytes 
that would normally display a reduced regenerative potential or even replicative 
senescence (the ‘telomerase switch’)312–314. Indeed, TERT overexpression is 
observed in most of the HCCs and this overexpression occurs  either by promoter 
mutation (60% of cases) or by focal amplification (5%)304,309,315.  
TERT alterations are occurring in the early stage of hepatocarcinogenesis, while 
most of the genetic diversity among HCCs seems to happen at a later stage. In 
progressed HCC one of the most commonly altered pathways in the WNT-β-catenin 
signaling cascade. In fact, activating mutations in the CTNNB1 gene occurs in 27% of 
HCC cases316. Other mutations also frequently affecting this pathway are deletions or 
inactivating mutations in AXIN1 (8% of all cases)316. Alterations in the cell-cycle are 
also major defects in HCC and mutations of TP53 are the most common in HCC with 
31% of all cases316. RB1 mutations (4%) and CDKN2A (2%) are also frequently 
mutated and in general all the molecular defects in the cell-cycle checkpoints are 
associated with poor prognosis and a more aggressive phenotype316,317,304. Chromatin 
remodelling complexes and epigenetic regulators are also frequently altered in HCC. 
In particular, AT-rich interaction domain genes ARID1A and ARID2 are mutated in 7% 
and 5% of the cases, respectively316. Interestingly, DNA methylation is globally altered 
in HCC and these aberrant modifications are in general also associated with 
prognosis318.  The RAS–RAF–MAPK (MAP kinase) and the phosphoinositide 3-kinase 
(PI3K)–AKT–mTOR pathways are also frequently activated in HCC. These changes 
are mainly caused by amplification of a region that includes CCND1 and FGF19 in 
approximately 6% of tumours, and can also be related to deletions in the phosphatase 
and tensin homologue (PTEN) (7% of cases), whereas mutations that activate RAS 
proteins themselves are rarely identified (<2% of cases)316.  
Genomic and transcriptomic data from large HCC cohorts have revealed different 
molecular sub-classes of HCC319,320. Unfortunately, a direct translation of molecular 
HCC subclasses into clinical management has not yet been achieved. This is mainly 
due to the absence of a consensus molecular classification system. Some of the 
published molecular classification systems319,321 can be partially summarized into two 
main classes: the proliferation and the non-proliferation class 319,320, each representing 





approximately 50% of patients. The proliferative class is characterized by activation of 
RAS/MAPK-, mTOR-, NOTCH- and insulin-like growth factor (IGF) signalling and by 
amplification in the FGF19 locus; it is correlated with poor histological differentiation 
and worse outcome319,321. Some authors have actually proposed that the proliferative 
subtype could be additionally divided in sub-groups: the WNT–transforming growth 
factor-β (TGFβ) group and the progenitor cell group. The progenitor cell group is 
enriched in progenitor cell markers, such as epithelial cell adhesion molecule, and the 
overexpression of α-fetoprotein (AFP)322. The non-proliferative class is more 
heterogeneous, but is often characterized by CTNNB1 mutations and it usually 
correlates with better outcome322,323. 
5.1.7. Class I Homeobox (HOX) genes and their role as master regulator of 
embryonic development 
In the early 1900s, by observing the phenotype of Drosophila melanogaster 
mutants, Morgan and Bridges hypothesized the existence of genes responsible for the 
correct spatial body development in fruit flies324. 70 years later the homeotic genes 
and their structures  were confirmed325,326 and highly conserved homologues were 
identified in most animals327–329. Homeotic genes are transcription factors sharing a 
highly conserved DNA sequence of 180 bp. This so called “homeobox” encodes the 
homeodomain (HD), a 60 amino-acid polypeptide involved in the DNA binding330,331. 
Overall, about 15–30 % of all transcription factors in animals are HD proteins332, which 
represents about 0.5–1.25 % of all proteins in a given species. HD transcription factors 
are essential for a plethora of biological functions:  in vertebrates, they act from the 
earliest stages of development onward333 and are essential in embryonic stem cell 
differentiation334,335.  
Many homeobox genes are organized in chromosomal clusters, with the number 
of clusters varying according to the anatomic complexity of the species. The best 
known  cluster so far is the cluster of the Class I Homeobox genes (Hox in mouse, 
HOX in humans), which correspond to the Drosophila Antennapedia complex and the 
Bithorax complex336–338. In humans 39 HOX genes have been identified, distributed 
over 4 chromosomal loci, each containing between 9 and 11 members that aligned 
into 13 paralogous groups339,340 (Figure 5.7).  





FIGURE 5.7. HOX genes in mouse and human with their phylogenetic counterparts in 
Drosophila. 39 HOX genes are involved in the mouse and human vertebral column, found in 
four clusters of HOX A, B, C and D on four chromosomes (6, 11, 15 and 2). 3’ HOX genes are 
expressed early in development in anterior regions, followed by progressively more 5’ genes 
expressed later and in posterior regions. Created with Biorender.com. 
 
HOX genes play crucial roles in regulating the formation of distinct anatomical 
regions through the maintenance of spatio-temporal collinearity across the anterior-
posterior body axis341–345. In order to do so, they are activated in a precise temporal 
and spatial sequence that follows their chromosomal order (the "HOX clock"): 3’ HOX 
genes (retinoic acid-responsive) are expressed early in development in anterior 
regions, followed by progressively more 5’ genes (FGF-responsive) expressed later 
and in posterior regions. In adult, HOX genes maintain tissue homeostasis by 
preserving the spatio-temporal coordinates established during embryonic growth, with 
each adult organ and sub-organ compartment displaying a unique combination of HOX 
gene expression346. The clustered HOX genes also control differentiation and self-
renewal of hematopoietic stem and precursor cells. The HOXA cluster in particular, 
and to a lesser extent the HOXB, are highly expressed in hematopoietic precursors347.  





HOXA13 is the most posterior of the HOXA cluster genes and during 
embryogenesis is expressed later and mainly in the genital tubercle and in the 
forelimbs348,349.  Indeed, HOXA13 has been shown to play a fundamental role in 
urogenital tract350, especially prostate351,352, and limbs353,354 morphogenesis, as well 
as to be involved in the interdigital programmed cell death (IPCD)353. Mutations in the 
HOXA13 gene, in fact, are associated with synpolydactyly and with the hand-foot-
genital syndrome355,356, a rare condition that affects the development of the hands and 
feet, the urinary tract, and the reproductive system. In agreement with these findings, 
mice lacking Hoxa13 exhibit reduced levels of IPCD349. HOXA13 has also been found 
to play a crucial role in extra-embryonic vascularization of the placenta and endothelial 
specification344, by directly regulating Ephrin type-A receptors 6 and 7357. Thus, 
controlling the expression of a number of genes via its transcriptional factor activity, 
HOXA13 can regulate the cell fate.  
 
5.1.8. Dis-regulation of HOX genes in tumorigenesis  
As previously mentioned, deregulation of pathways normally active during 
embryonic development is a common feature of human malignancies. Therefore, is 
not surprising to find dysregulation of the HOX genes in many human cancers358,359, 
especially hematological malignancies360. There are three main modalities through 
which homeobox gene alterations are presented in cancer, defined by Abate-Shen in 
2002361. In the first scenario, homeobox genes that are normally only active during 
embryonic development are “re-expressed” in neoplastic cells. This group accounts 
for the majority of HOX aberrations. A second possibility, instead, is that a homeobox 
gene can be expressed in cancer cells derived from tissue in which this particular gene 
is not expressed during embryogenesis. This is for instance the case of PAX5 
expression in medulloblastoma362, but not in the cerebellum, the tissue from which 
medulloblastoma derived and it is also the case of HOXA13 overexpression in 
hepatocellular-carcinoma362,363, further discussed in this thesis.  At last and less 
commonly, homeobox genes can also be down-regulated in malignant cells derived 
from tissues in which a particular HOX gene is normally expressed in the fully 





differentiated state (Figure 5.8). Loss of expression of CDX2 and NKX3.1 in colon 
cancer are classical examples of this last mechanism.  
 
Figure 5.8. Modalities of Hox genes alterations in cancer. Homeobox genes normally 
expressed in developing tissues and downregulated in differentiation are often re-expressed 
in cancer. Conversely, homeobox genes that normally expressed in differentiated tissues are 
often downregulated in cancer progression. Figure obtained from Abate Shen, 2002361.  
 
As already said, homeobox genes are important regulators of normal 
hematopoiesis, being preferentially expressed in hematopoietic stem cells (HSC) sub-
populations and progenitors cells. During differentiation and maturation of the 
hematopoietic compartment, HOX genes are downregulated364,365. In this context is 
not hard to imagine how altered expression of HOX genes, HOXA cluster in particular, 
could result in leukemogenesis by blocking or delaying hematopoietic 
differentiation366,367. Dysregulation of the homeobox genes in leukemia often happens 
through major chromosomal translocations or minor DNA rearrangements which result 
in the overexpression of the homeodomain-containing proteins368. A typical example 
is the fusion of the NUP98 gene with many HOXA genes, among which HOXA9369,370 
and HOXA13371. These fusions typically result in up-regulation of the HOXA cluster 
genes and HOX-NUP98 fusion genes expression in mice has been proven to be 
leukemogenic372,373. Chromosomal rearrangements can affect HOX genes expression 
in leukemia also indirectly. For instance, the MLL gene, human homolog of the 
Drosophila trithorax, maintains HOX gene expression in mammalian embryos374,375 
and is rearranged in human leukemias resulting in Hox gene deregulation. In 





particular,  HOX gene expression is upregulated in human leukemias carrying MLL 
rearrangements376,377, and transformation of murine bone marrow by MLL fusion 
proteins is HOX gene dependent378, thus suggesting that deregulation of HOX gene 
expression is pivotal for MLL-associated leukemogenesis.  
 
While the oncogenic role of many HOX genes in leukemia has been well 
described, their role in other malignancies is currently being studied. However, it is 
now clear that homeobox genes, including HOX and non-HOX genes, are aberrantly 
expressed also in solid tumors. In gastrointestinal cancers, most studies have focused 
on the function of non-HOX. However,  more recently several HOX genes were 
reported to play specific roles in gastrointestinal cancers.  For instance, HOXB7 
upregulation has been shown to promote tumorigenesis and cancer progression in 
stomach and colorectal cancers379–381. HOXD10, on the contrary, is upregulated in 
colorectal cancer while it is silenced epigenetically in gastric cancer382,383. Therefore, 
it looks clear now that expression pattern of various homeobox genes differ among 
specific tumor types or cell lineages. HOXB13 is another example that is upregulated 
in breast cancer384 but downregulated in prostate cancer381,385. Another example is 
HOXA9, previously mentioned for its role in leukemia where it is found upregulated. 
On the contrary, HOXA9 is down-regulated in lung cancer cells through an epigenetic 
silencing mechanism386.  
 
Homeobox genes are also transcriptionally regulated by several long and short 
non-coding RNAs (lncRNAs)387,388 and these have also been found to play a role in 
cancer. Up to date, 231 ncRNAs have been annotated within the 4 HOX loci389. 
In particular, recent studies focusing on dosage compensation, imprinting and 
homeotic gene expression suggest that individual lncRNAs can function as an 
interface between DNA and specific chromatin remodelling activities. Enforced 
expression of the HOX transcript antisense intergenic RNA (HOTAIR), a long non-
coding RNA located in the HOXC locus, for instance, induces genome-wide re-
targeting of Polycomb repressive complex 2 (PRC2) leading to altered methylation 
patterns, gene expression, and increased cancer invasiveness and metastasis390. 
HOTAIR has been reported to play a role in several solid tumors, among which small 





cell lung cancer391 and breast cancer390. MicroRNAs (miRNAs) are also located within 
the HOX clusters and target multiple HOX genes to regulate their expression post-
transcriptionally392.  
 
Because many HOX genes are found to be aberrantly expressed in multiple 
different cancer types, it has been speculated that there may be similar HOX-related 
regulatory networks that become dysregulated during cancer development. However, 
the role of HOX genes, and particularly genes targeted by HOXs transcriptional 
control, is poorly defined and the functional relationship between the malignant 
phenotype and abnormal expression of these genes is still unclear. Attempts to 
elucidate the function of HOX genes in malignant transformation will be enhanced by 
a better understanding of their upstream regulators and downstream target genes.  
5.1.9. The role of HOXA13 in carcinogenesis  
Aberrant expression of the HOXA13 gene or its associated long non-coding RNA 
HOXA transcript at the distal tip (HOTTIP),  has been seen in several solid tumors, 
among which gastric393, bladder393,394, esophageal382,395, prostate396 and thyroid 
cancer388,397, glioma398 and hepatocellular carcinoma (HCC)396,399,400. In fact, HOXA13 
overexpression is significantly associated with lymph node metastasis and, more 
generally, it correlates with poor overall survival, histological grades and TNM stage 
in human cancers. Therefore, HOXA13 might be considered a valuable biomarker of 
poor prognosis398,401.  
 
The detailed molecular mechanisms through which HOXA13 is involved in tumor 
development and/or progression have been only preliminary exploited, but in recent 
years several research lines have shown the involvement of HOXA13 in many well 
studied cellular networks known to be deregulated in cancer. As above mentioned, 
HOXA13 is required for extraembryonic vascularization344 and directly regulates 
Ephrin type-A receptors 6 and 7 in the developing genital tubercle vasculature357, 
suggesting a possible involvement of HOXA13 in the promotion of cancer cell growth 
by stimulating angiogenesis. More recently, it has been shown that HOXA13 
knockdown in oesophageal squamous cancer cell lines is accompanied by loss of 





Annexin-A2 and antioxidant enzyme MnSOD, both involved in cell proliferation and 
carcinogenesis395.  Upregulation of HOXA13 has also been linked to the activation of 
the Wnt402 and TGF-β signalling pathways398,403, suggesting that it may contribute to 
the epithelial-to-mesenchymal transition (EMT). In gastric cancer HOXA13 
overexpression has been shown to promote proliferation and metastasis at least partly 
via activation of Erk1/2404. Additionally, HOXA13 has been linked to apoptosis 
inhibition and increased resistance to chemotherapy405,406, as well as resistance to 
targeted therapy363.  
 
Among the HOX genes, HOXA13 has been reported to be the most deregulated 
in HCC399,407,408. Our group, in particular, reported for the first time that high HOXA13 
and HOTTIP expression in HCC is linked with disease progression and predicts 
patients’ survival396,399,400.  Notably, HOXA13 and HOTTIP co-expression was found 
to be associated with disease progression, metastasis formation and worse clinical 
outcome in HCC patients399, suggesting that the molecular axis controlled by HOXA13 
and HOTTIP plays a pivotal role in HCC progression399. 
FIGURE 5.9: HOXA13 expression level is associated with disease progression in HCC. 
(A) HOXA13 is up-regulated in HCC samples compared to their matched non-tumoral 
counterpart as well as non-neoplastic liver specimens. (B) Patients developing metastasis 
present the highest expression levels of HOXA13. (C) Survival plots of 52 HCCs including 
both untreated and HCC-treated patients analysed using the Kaplan-Maier method. ROC 
analysis was used to discriminate between HIGH and LOW expressing samples. HIGH 
HOXA13 expression results in shorter patient survival. *p: ≤ 0.05 (Modified from Quagliata et 
al.399) 





Over the last years, our research group has continued to work on understanding 
the role of the HOXA13 gene in hepatocarcinogenesis. In one study, taking advantage 
of a tissue microarray containing 305 tissue specimens, we found that HOXA13 protein 
expression increased monotonically from normal liver to cirrhotic liver to HCC (Figure 
5.10)363. In two independent cohorts, patients with HOXA13-positive HCC had worse 
overall survival than those with HOXA13-negative HCC (Figure 5.10)363. Stable 
overexpression of HOXA13 in liver cancer cell lines resulted in increased colony 
formation in soft agar and migration potential as well as reduced sensitivity to sorafenib 
in vitro (Figure 5.10)363.  
FIGURE 5.10: HOXA13 is a putative novel oncogene in HCC. (A) Percentage of HOXA13-
positive and HOXA13-negative normal, cirrhotic and tumoral livers. (B) Overall survival of 115 
and 43 HCC patients in two independent cohorts. (C) Representative micrographs of colonies 
in HOXA13-overexpressing (right) and matched control cells (left). (D) Migration potential of 
HOXA13-overexpressing cells and matched control cells at 12, 24 and 36 hours post seeding 
(Modified from Quagliata et al.363). 
  





5.2 Aim of the research project 
 
HOX genes are commonly found dysregulated in many human cancers. Among them 
HOXA13, in particular, has been found to be the most overexpressed in HCC and to 
be associated with poor prognosis and resistance to sorafenib. However, no previous 
work has shown so far a direct causal effect between HOXA13 overexpression and 
liver tumorigenesis. 
 
With the present research project we aimed to prove the direct oncogenicity of 
HOXA13 in the liver. In particular, in the first part of the project we aimed to develop a 
model of stable Hoxa13 overexpression in the normal hepatocytes of adult mice and 
to characterize this model. In the second part of the project, we aimed to unravel the 
molecular mechanisms of Hoxa13-induced liver tumorigenesis and to identify HOXA13 
putative downstream targets through a multi-omic approach coupling transcriptomic 
and genomic data obtained both in vivo and in vitro.  






5.3.1. Mice experiments 
6–8-week C57Bl/6 mice were obtained from Jackson Laboratory. All animals were 
housed in a pathogen-free barrier facility in accordance with the Helmholtz Zentrum 
München, Ludwig-Maximilians-University München, Technical University München 
and institutional, state and federal guidelines. All animal studies were conducted in 
compliance with European guidelines for the care and use of laboratory animals and 
were approved by the Institutional Animal Care and Use Committees (IACUC) of 
Technische Universität München, Regierung von Oberbayern, and the UK Home 
Office.  
5.3.2. Hydrodynamic tail vein injection 
To transfect hepatocytes in vivo, 10μg/mL of highly purified plasmids to be 
transfected were dissolved in approximately 2 ml of 0.9% physiological saline solution 
(10% of body weight of 6-8 weeks old mice, e.g. 18-25 g). After immobilization of the 
test animal in a suitable device, the warming of the mouse tail took place under a red-
light lamp for dilatation of the veins. The mouse was under continuous monitoring 
(activity, respiratory rate) to prevent overheating. With sufficient visibility of the tail 
veins (usually after 3 to 5 min), the plasmids were injected by means of a 3 ml syringe 
and a 27G cannula over a period of 8 to 10 sec. The mouse was then immediately 
removed from the immobilization tube and the injection site compressed for 30 
seconds or at least until the suspension of any rebleeding. Then the mouse was reset 
in the cage. A transient high volume pressure usually leads to slight sedation of the 
mouse over 1 to 2 hours. During this time the general condition and activity were 
checked every half hour. Animals were sacrificed as soon as hepatic tumors were 
diagnosed or when signs of sickness were apparent. 
5.3.3. Histology and immunohistochemistry 
 
Paraformaldehyde (4%)-fixed and paraffin-embedded liver, spleen, pancreas, 
kidney and lung tissues were cut as 3.5-μm thick sections. Hematoxylin and eosin 
(H&E) staining was performed according to standard protocols. Immunohistochemistry 





was conducted using primary antibodies listed in the table  at the end of this section. 
The staining was performed on a BOND-MAX immunohistochemistry robot (Leica 
Biosystems) with BOND polymer refine detection solution for DAB. Images were 
obtained by scanning of whole tissue sections with a Leica SCN400 slide scanner. 
Tissue areas positively stained for HOXA13, Ki67, yH2AX and cleavage-Caspase 3 
were quantified manually as percentage or absolute number (positive cells per total 
cells) and normalized to the total tissue area. For the quantification of the percentage 
of cells positively stained, four different areas were randomly selected and analyzed 
by researchers 'blinded' to sample identity with a SCN400 slide scanner analysis 
software (Leica). 
 
5.3.4. Cloning and vectors 
The pShuttle ™ Gateway® PLUS vector expressing the Mus musculus homeobox 
A13 (Hoxa13) ORF was purchased from GeneCopoeia (Catalog #GC-Mm03081). The 
pEGFP-N1 was purchased from Clontech (Catalog #6085-1). Both Hoxa13 and EGFP 
were cloned under a human liver-specific promoter409 in a transposon vector (ApoE-
pTC) containing the Sleeping Beauty transposase (SB5) inverted repeats, as  
previously described410. More in detail the murine ORF of Hoxa13 and EGFP were 
amplified from their respective expression vectors using primers listed below. Each 
primer was designed to contain a leader sequence (KOZAC), the restriction enzyme 
sequence and the hybridization sequence. Subsequently the obtained amplified PCR 
products were cut with the PacI e AscI restriction enzymes and ligated into the ApoE-
pTC vector. Subsequently the promoter and the ORF of Hoxa13 were amplified  by 
PCR with new primers (pA1-Fwd and pA1-Rev, see table) and sub-cloned together 
into a second transposon vector using  the SpeI and XbaI restriction enzymes. For 
EGFP we used the same cloning primers and restriction enzymes used for the first 
cloning. The new transposon vector (pA1) contained the inverted repeats of a 





hyperactive version of the Sleeping Beauty (SB100) and it was kindly provided by the 
research group of Dr. Roland Rad from the Technical University of Munich and 
previously described by them411.  
 
The pCMV(CAT)T7-SB100 (addgene #34879) vector encoding for a hyperactive 
Sleeping Beauty was used as transposase vector and co-injected together with the 
transposon vector encoding for Hoxa13 or for EGFP.  
 
For the in vitro experiments the vector containing the human ORF of HOXA13 
under a CMV promoter and its relative control vector were previously described363. For 
the overexpression of the HA-tagged HOXA13 the pRP[Exp]-CMV-HA/hHOXA13 was 
designed and ordered on the Vector builder platform (NM_000522.4), together with 
control vector pRP[Exp]-CMV-EGFP.  
 
 
5.3.5. RNA isolation, cDNA synthesis and Real-time PCR 
For in vivo experiments total RNA from fresh frozen liver tissue of C57BL/6 mice 
was isolated using RNeasy Mini Kit (Qiagen) and tissue disruption with gentleMACS 
Dissociator (Macs Miltenyi Biotec). The quantity and quality of the RNA was 
determined spectroscopically using a Nanodrop (Thermo Scientific). 1 ug of purified 
RNA was reversely transcribed into cDNA using Quantitect ReverseTranscription Kit 
(Qiagen) according to the manufacturer’s protocol. For mRNA expression analysis 
real-time PCR (RT-PCR) was performed using Fast Start SYBR Green Master Rox 
(Roche). Real-time PCR was performed on an ABI PRISM 7900 HT Fast Real-Time 
PCR System (AB). Data were generated and analyzed using SDS 2.4 and RQ 
manager 1.2 software.  





For in vitro experiments total RNA was extracted from cells at 75% confluence 
using TRIZOL (Invitrogen, Carlsbad, CA, USA) according to manufacturer's 
guidelines. cDNA was synthesized from 1 μg of total RNA using SuperScript™ VILO™ 
cDNA Synthesis Kit (Invitrogen).  All reverse transcriptase reactions, including no-
template controls, were run on an Applied Biosystem 7900HT thermocycler. The 
expression of all the genes was assessed by using FastStart Universal SYBR Green 
Master Mix (Merk, CO; #4913850001) and all qPCR performed were conducted at 
50°C for 2 min, 95°C for 10 min, and then 40 cycles of 95°C for 15 s and 60°C for 1 
min on a QuantStudio 3 Real-Time PCR System (Applied Biosystems).  
For all RT-PCR experiments the specificity of the reaction was verified by melting 
curve analysis. Measurements were normalized using the murine Gapdh or the human 
GAPDH levels as reference. The fold change in gene expression was calculated using 
the standard ΔΔCt method as previously described228. All samples were analyzed in 
triplicate.  Primers were custom made by Microsynth and are listed at the end of this 
section. 
5.3.6. RNA sequencing 
Ion AmpliseqTM Transcriptome Mouse Gene expression kit (A36553) from Ion 
Torrent (Thermo Fisher Scientific) was used for library preparation following the 
datasheet guidelines. RNA extraction was performed using TRIZOL method followed 
by tissue disruption with gentleMACS Dissociator (Macs Miltenyi Biotec). RNA was 
extracted from whole liver extracts of mice overexpressing Hoxa13 after 2 weeks post 
HTVI (n=3) or EGFP vector (n=3), liver tumors from 48-weeks post HTVI mice (n=3) 
and respective 48-weeks mice liver controls (n=3). RNA samples were treated with 
Turbo Dnase (AM 1907, Thermo Fisher Scientific) and quantified using a Qubit 
Fluorometer (Life Technologies). RNA integrity was measured using the Agilent 
Bioanalyzer 2100 (Agilent Technologies). 10 ng of RNA for each sample was then 
reverse transcribed using the SuperScript VILO cDNA synthesis kit (Thermo Fisher 
Scientific) and resuspended in a final volume of 15 μl. The cDNA was amplified for 12 
cycles using the Ion AmpliSeqTM Transcriptome Mouse Gene Expression Core Panel 
that targets over 20,000 mouse RefSeq genes (23,930). The resulting pool of libraries 
was then quantified by qPCR using the Ion Universal Quantification kit (Thermo Fisher 





Scientific). Expected dilution was around 100 pM. The pool was then diluted to a 50 
pM final concentration and loaded on an Ion 540TM chip using the Ion ChefTM 
instrument and sequenced on an Ion S5TM instrument (Thermo Fisher Scientific).  
Raw data was processed directly on the Ion Torrent ServerTM and aligned to the 
Mus musculus genome assembly GRCm38.p5 reference. Absolute reads matrix was 
downloaded from the Ion Torrent server and the differential analysis was performed 
using edgeR package 
[https://academic.oup.com/bioinformatics/article/26/1/139/182458/]. Genes with low 
expression (< 1 log-counts per million in ≥ 1 sample) were filtered out. Normalization 
was performed using "TMM" (weighted trimmed mean) method and differential 
expression was assessed using the quasi-likelihood F-test. Genes with false discovery 
rate (FDR) < 0.05 were considered differentially expressed.  
Pathway enrichment analysis was performed with the upregulated genes using 
clusterProfiler package [https://www.liebertpub.com/doi/10.1089/omi.2011.0118]. 
Chromosomal instability of the samples was checked by using the CIN25 and 
CIN70 signature genes from Carter et al.412,413. 
5.3.7. Cell lines 
HCC-derived cell lines (HepG2 and Huh-7) were maintained in a 5% CO2-
humidified atmosphere at 37°C and cultured in DMEM supplemented with 10% FBS, 
1% Pen/Strep (Bio-Concept) and 1% MEM-NEAA (MEM non-essential amino acids, 
ThermoFisher Scientific). Both cell lines were confirmed negative for mycoplasma 
infection using the PCR-based Universal Mycoplasma Detection kit (American Type 
Culture Collection, Manassas, VA) as previously described414 . Cells were stably 
transfected using the jetPRIME transfection reagent (Polyplus) following the 
manufacturer’s instructions and then kept under antibiotic selection. 





5.3.8. Chromatin Immunoprecipitation (ChIP) assay  
For ChIP a previously described Nature Protocol415 was used and adapted for the 
experiment. Cells from four 100 cm Petri dishes at 70-80% confluence were 
crosslinked in 1% formaldehyde for 10 min with continuous shaking. Crosslinking was 
stopped by addition of 0.15 M glycine while continuing shaking. After collecting cells 
by scraping, pellets were washed 3x with cold PBS. Nuclei were isolated and lysed 
and the obtained chromatin was sonicated in fragments of approximately 200 bp using 
the Bioraptor instrument. Number of cycles and settings for sonication were previously 
described 416.  At the same time, antibodies used for immunoprecipitation were 
coupled with magnetic protein G beads (Invitrogen 100-03D) by incubating 75 μl of 
protein G beads with 10 μg of anti-HOXA13 antibody (anti human HOXA13 abcam, 
#ab106503), anti-HA tag antibody (abcam anti-HA tag ChIP grade  #ab9110)  or 10 
μg of mouse IgG ( Santa Cruz Biotechnology, #sc-2025) as a negative control for 1h 
at room temperature with constant rotation. At the end of the sonication process, an 
aliquot of chromatin was kept as input control for each sample and an equal amount 
of sonicated chromatin was incubated with magnetic beads-antibody previously 
coupled  at 4°C overnight while rotating. After incubation, samples were washed 
several times and then eluted according to the protocol described by Blecher-Gonen 
et al.415. All the samples including the input were processed for RNase and Proteinase 
K treatment, followed by overnight reverse cross-linking at 65°C with continuous 
shaking. DNA purification followed using Agencourt AMPure XP (A63880 Beckman 
Coulter). Library construction was performed using the NEBNext® Ultra™ DNA Library 
Prep Kit for Illumina® preparation kit according to the standard protocol. Massively 
parallel sequencing was performed on an Illumina NextSeq 550 according to 
manufacturer’s instructions. 50 million reads per sample were obtained.  
ChIP-seq reads were aligned to the human reference genome GRCh38 using 
BWA417. Enriched regions of the genome were identified from the merged alignment 
files relative to input control using MACS2418. Consensus peak files were generated 
for HepG2 and Huh-7 using bedtools to merge peaks called from the HOXA13 specific 
ChIP with the ChIP for HA-tagged HOXA13. This resulted in 117,010 peaks for HepG2 
and 40,657 for Huh-7. Peaks were annotated with their nearest gene, and genomic 





feature, using  the annotatePeak function from the ChIPSeeker package and the 
GRCh37.75 Ensembl annotation database for the hg19 human genome assembly.  
Peaks were annotated as ‘Promoter’ if they were < 3 Kb either side of a TSS. Peaks 
not annotated as ‘Promoter’ were annotated with the following hierarchy 5’UTR, 
3’UTR, Exon, Intron, Downstream, Intergenic. The mouse-derived RNA-seq data were 
integrated with HOXA13 ChIP seq data from the two human liver cell lines. The human 
orthologue for each gene defined as differentially expressed in the mouse ‘overall’ 
dataset (p < 0.xx, Log2FC > ± x) was annotated with the nearest peak called in both 
HepG2 and HUH7, along with the total number of peaks associated with the gene in 
both lines. These data were used to create a ‘Peak score’, reflecting the strength of 
the association between the ChIP-seq signal in the human cell lines, and the gene, as 
a function of the presence of associated peaks in the human cell lines, the total number 
of associated peaks, and the distance of the closest peaks from the gene’s TSS. This 
was calculated as follows. First a ‘line count’ was generated for each DE gene, 
whereby if the gene had associated peak in neither line it was given a line count of 1, 
if it had an associated peak in one line it was assigned a line count of 2, and a line 
count of 3 if annotated in both lines. This number was multiplied by the total number 
of associated peaks in both lines. This value was finally divided by the log of the 











5.4.1. Establishment of a liver-specific Hoxa13 overexpressing mouse model 
using hydrodynamic tail vein injection 
To overexpress HOXA13 in mature hepatocytes, we constructed a Sleeping 
Beauty transposon coding for the murine ORF of Hoxa13 under the control of a 
hepatocyte-specific promoter410 (Figure 5.11). We co-injected C57Bl/6J wild-type 
mice with this transposon vector together with a plasmid encoding for a mutated 
hyperactive form of the Sleeping Beauty transposase (SB100)(Figure 5.11). This 
transposon stably integrates into a low percentage of liver cells following 
hydrodynamic tail vein injection (HTVI) (approximately 10 percent of hepatocytes).  As 
control, we injected a comparable number of C57Bl/6J mice with a control vector 
coding for EGFP under the same liver-specific promoter as with Hoxa13 together with 
the SB100 transposase vector (Figure 5.12). In this way we assured that also the 
control hepatocytes were going through the same random integration process into the 
genome and the same putative liver damage induced by the hydrodynamic injection 
per se.  
 
FIGURE 5.11. Schematic representation of the cloning strategy and hydrodynamic  tail 
vein injection. The murine Hoxa13 ORF was  cloned under the control of a hepatocyte-
specific promoter flanked by inverted repeats recognized by the Sleeping Beauty transposase. 
The transposon vectors were co-injected with the transposase (SB100) plasmid, thus allowing 
the stable integration into a low percentage of liver cells following hydrodynamic tail vein 
injection. A control vector encoding EGFP ORF instead of Hoxa13 was also cloned in the 
same transposon vector and injected in control mice. Created with Biorender.com. 





Eight mice for each experimental group (Hoxa13OX or EGFPox/control group) were 
injected and euthanized at different time points (Figure 5.12). Specifically, mice were 
sacrificed after 2, 4, 12 and 20 weeks following hydrodynamic tail vein injection. 
Additionally, eight mice for each group (Hoxa13OX or EGFPox/control group) were kept 
over long-term (up to 48 weeks post injection) and monitored for liver tumor formation. 
FIGURE 5.12. Schematic representation of the cloning strategy and hydrodynamic  tail 
vein injection.  For each experimental group, eight mice were injected and sacrificed at 
several time points. Additionally eight mice for each group (Hoxa13OX or EGFP/control group) 
were kept over long-term (up to 48 weeks post injection) and monitored for liver tumor 
formation (last endpoint). Created with Biorender.com. 
The first endpoint was initially used to screen the transposase systems and 
assess the stable overexpression of both transposons. For this time point an additional 
experimental group of mice injected with the transposase vector only (negative control) 
was added. In detail, after two weeks of recovering, mice were euthanized and organs 
harvested in order to check Hoxa13 and EGFP expression at the mRNA level by qPCR 
and at the protein level by IHC and fluorescence microscopy. As shown in Figure 5.13, 
EGFP was overexpress at both at the mRNA and protein levels two weeks post 
injection (Figure 5.13- A,B). EGFP expression level was also followed over time and 





resulted stably overexpressed up to 12 weeks post hydrodynamic injection (Figure 
5.13, B).  
 
FIGURE 5.13. EGFP expression at the different endpoints. (A) Representative 
fluorescence microscopy of frozen liver sections (10 μm) of mice injected with SB100 
transposase only (control) and EGFP transposon (EGFPox) after two weeks post 
hydrodynamic injection. (B) mRNA expression level of EGFP after 2, 4 and 12 weeks post 
injection.  
Hoxa13 expression was detected up to 20 weeks post-injection, both at the mRNA 
and protein levels (Figure 5.14), confirming that the system achieved  hepatocyte-
specific Hoxa13 overexpression in approximately 10% of the hepatocytes.  
 
FIGURE 5.14. Hoxa13 expression at the different endpoints. (A) Representative images 
of hematoxylin-eosin and IHC staining for HOXA13 of FFPE liver sections (4.5 um) of mice 
injected with EGFP (control) and Hoxa13 transposon (Hoxa13ox) after two weeks post 





hydrodynamic injection. (B) mRNA expression level of EGFP after 2, 4, 12 and 20 weeks post 
injection.  
 
As shown in Figure 5.14, Hoxa13 expression was detected up to 20 weeks post-
injection, both at the mRNA and protein levels, confirming that the system achieved  
hepatocyte-specific Hoxa13 overexpression in approximately 10% of the hepatocytes.  
5.4.2. Hoxa13 overexpression drives hepatocytes proliferation and DNA damage 
in vivo 
To assess the phenotype induced by Hoxa13 overexpression in vivo, according 
to the experimental plan mice were sacrificed at 3 endpoints: 2, 4 and 12 weeks post-
injection. Proto-oncogenes perform physiological functions that are necessary for 
normal cellular homeostasis. In particular, proto-oncogenes control the processes of 
growth, proliferation, and survival that a cancer cell can exploit to gain competitive 
advantages over its non-neoplastic counterparts1. If Hoxa13 is a putative proto-
oncogene we hypothesis that its overexpression should have an effect on proliferation 
and also induce a certain amount of cell stress and apoptosis. Therefore, we 
performed immunohistochemical stainings to assess the rate of hepatocyte 
proliferation, DNA damage and other stress-related markers. In particular, the rate of 
proliferation of the hepatocytes was assessed by staining the whole liver sections for 
the proliferation-related protein Ki67 (Figure 5.15). Of note, all mice overexpressing 
Hoxa13ox showed a significant increase in proliferative hepatocytes (Ki67+ 
hepatocytes), compared to the EGFPox/control group (Figure 5.15). The strongest 
proliferative phenotype was observed two weeks post-injection and progressively 
reduced with the age of the mice and the time distance respect to HTVI, while the 
difference between the two groups (EGFPox and Hoxa13ox ) was kept significant up to 
twelve weeks post hydrodynamic injection (Figure 5.15). 






FIGURE 5.15. Hoxa13 overexpression drives hepatocytes proliferation. (A) 
Representative images of IHC staining for Ki67 antibody on FFPE liver sections (4.5 um) of 
mice injected with EGFP (EGFPox) and Hoxa13 transposon (Hoxa13ox) after 2, 4 and 12 weeks 
post hydrodynamic injection. (B) IHC quantification (+ hepatocytes normalized to tissue area) 
of Ki67 staining. 
“Intrinsic tumor suppression” activities such as cellular senescence or apoptosis 
are usually triggered when a cell is driven to uncontrolled proliferation through the 
inappropriate activity of a proto-oncogene1,419. We asked whether this was also the 
case for Hoxa13 overexpression and we therefore stained hepatocytes with an 
antibody against cleaved (Asp175) Caspase 3 (Cl. caspase3), commonly used as a 
marker of apoptosis. Two weeks post injection some of the Hoxa13ox hepatocytes were 
positively stained for Cl. caspase 3 (Figure 5.16, A). When co-stained with HOXA13 
antibody, Cl. caspase 3 positivity overlapped with HOXA13 signal, indicating that the 
apoptotic hepatocytes were some of the ones overexpressing HOXA13 (Figure 5.16, 
A). When checking Cl. caspase 3 staining at 4 and 12 weeks post HTVI, there was not 
a statistically significant difference between the EGFPox and the Hoxa13ox  mice, 





indicating that the tumor suppressive mechanisms were acting earlier after 
hydrodynamic injection leading later to a stabilized situation in which the hepatocytes 
able to escape the intrinsic anti-tumor apoptosis were kept proliferating (Figure 5.16, 
B).  
 
FIGURE 5.16. Hoxa13 overexpression induced oncogenic stress and apoptosis early 
post HTVI. (A) Representative images of IHC for H&E, single Cl. caspase3 and HOXA13 
staining and  HOXA13 (black) and Cl. caspase3 (red) double staining on FFPE liver sections 
(4.5 um) of mice injected with Hoxa13 transposon (Hoxa13ox) two weeks post hydrodynamic 
injection. (B) IHC quantification (+ hepatocytes normalized to tissue area) of Cl. caspase3 
staining at 2, 4 and 12 weeks, respectively. 
 
Genotoxic stress is another typical phenomenon induced by proto-oncogene 
overexpression which normally activates the DNA damage checkpoint in proliferating 
cells.   Thus, to drive proliferation, cells must tolerate DNA damage and suppress the 
checkpoint response. Considering the previously described results from the Cl. 
caspase 3 staining, we asked whether the apoptosis seen after 2 weeks post injection 
was a consequence of genotoxic stress induced by Hoxa13 overexpression. 





Moreover, considering that not all Hoxa13 overexpressing hepatocytes were apoptotic 
and that cell death was no longer induced at 4 and 12 weeks post HTVI, but that on 
the contrary hepatocytes were still actively proliferating more, we asked whether this 
could have led to DNA damage accumulation over time. DNA damage was assessed 
by staining the whole liver tissue sections of the mice with the γH2AX (pSer139) 
marker, which is a common marker of DNA double strand breaks. As shown in Figure 
5.17, liver of mice overexpressing Hoxa13 presented a significant increase in the 
number of γH2AX-positive hepatocytes compared to control mice overexpressing 
EGFP, suggesting a possible involvement of Hoxa13 in DNA damage and genomic 
instability. As with the proliferative phenotype, the number of the γH2AX-positive 
hepatocytes was significantly increased at all time points, with the strongest phenotype 
visible 2 weeks post-injection (Figure 5.17).  
 
FIGURE 5.17. Hoxa13ox livers show positivity for the DNA damage marker yH2AX. (A) 
Representative images of IHC staining for yH2AX antibody on FFPE liver sections (4.5 um) of 
mice injected with EGFP (EGFPox) and Hoxa13 transposon (Hoxa13ox) after 2, 4 and 12 weeks 
post hydrodynamic injection. (B) IHC quantification (+ hepatocytes normalized to tissue area) 
of yH2AX staining. 






We wanted to analyze deeper the phenotype induced by Hoxa13, especially the 
2 weeks phenotype, since we expected the early events induced by Hoxa13 
overexpression to be the ones dictating the cell phate. In particular, we asked whether 
Hoxa13 induced proliferation was a cell-autonomous or non-autonomous 
phenomenon. To discriminate if the proliferation induced by Hoxa13 was an autocrine 
or paracrine effect, we performed an IHC co-staining with Hoxa13 and Ki67 antibodies. 
As shown in Figure 5.18, Hoxa13 (red) and Ki67 (blue) only partially co-stain (purple), 
suggesting either a possible and additional paracrine effect mediated by Hoxa13 or 
the presence of compensatory proliferation as a results of the apoptotic process acting 
at 2 weeks post injection, as previously shown. 
 
FIGURE 5.18. IHC Double-staining in Hoxa13ox liver hepatocytes of 2 weeks post HTVI 
mice. Starting from the left, representative images (100μM and 50 μM magnification) of IHC 
double-staining for Hoxa13-Ki67, yH2AX-Ki67 and yH2AX-Hoxa13 antibodies on FFPE liver 
sections (4.5 um) of mice injected with Hoxa13 transposon (Hoxa13ox) 2 weeks post 
hydrodynamic injection. (B) IHC quantification (% of positive hepatocytes on total number of 
hepatocytes) of the double-staining. 
We asked the same for the DNA damage. In particular, due to the fact that the 
DBSs marker γH2AX often co-stain with the proliferation marker Ki67, we asked 





whether the presence of γH2AX positivity was a direct effect of a DNA damage 
mediated by Hoxa13 overexpression per se, or simply an indirect effect of hepatocyte 
proliferation. As shown in Figure 5.18, Ki67 and γH2AX (14% of total hepatocytes, in 
red) also only partially co-stained (5% of total hepatocytes, in purple), while Hoxa13 
co-stained with γH2AX 100% (8.7% and 9% of total hepatocytes, in purple and blue 
respectively), indicating that Hoxa13 overexpression per se may be able to drive DNA 
damage. We speculated that the remaining yH2AX positive-Hoxa13 negative 
hepatocytes may account for the remaining proliferating hepatocytes non-Hoxa13 
positive (approximately 6-7% of the Ki67 positive hepatocytes).  
5.4.3. Hoxa13 overexpression drives liver tumorigenesis in mice 1 year post 
HTVI 
Of note, 48 weeks post HTVI, 50% of the mice overexpressing Hoxa13 developed 
liver tumors of various histological grades and types, from very well differentiated 
HCCs to very undifferentiated and cholangiocarcinoma-like nodules (Figure 5.19). 
 
 Some of the mice also developed tumor metastasis in the lung and in the spleen. 
These data provide evidence that HOXA13 overexpression alone may be sufficient to 
drive liver hepatocarcinogenesis in vivo.  
 
 
FIGURE 5.19. Hoxa13 overexpression drives liver tumorigenesis in mice 1 year post 
HTVI. 1 year post HTVI 50% of mice overexpressing Hoxa13 developed tumors in the liver. 





Tumors positively stained for HOXA13 antibody (left, upper panel). Liver tumors and lung 
metastasis were additionally stained for CK-19 (cholangiocytes/stemness marker) and ARG1 
(hepatocytes marker).  
5.4.4. Gene expression analysis reveals commonly deregulated gene networks 
between 2 weeks livers and tumors 
To understand the mechanisms of hepatocarcinogenesis mediated by Hoxa13, 
we performed a transcriptomic analysis on tumors and livers of mice from 2 weeks 
post-injection, since those were the mice in which we obtained the strongest 
phenotype.  In particular, we aimed to identify the genes and pathways deregulated 
immediately after Hoxa13 overexpression (2 weeks post-injection) and the ones that 
were still upregulated in the tumors, since we expected that these genes may be the 
principal drivers of tumorigenesis. Consistent with our prediction, livers from 2 weeks 
Hoxa13ox mice and tumors from 1 year injected Hoxa13ox mice clustered in two distinct 
groups, control and Hoxa13ox respectively (Figure 5.20). Genes whose expression 
was deregulated in the livers from 2 weeks Hoxa13ox mice were also still deregulated 
in the tumors. Of note, for many of those genes the deregulation (most of the genes 
were upregulated upon Hoxa13 overexpression) was even incremented in tumors 
compared to 2 weeks, thus suggesting a possible involvement in the tumorigenic 
process. When we performed pathway enrichment analysis we found that most of 
those genes related to cell cycle, in particular G2/M transition and mitotic spindle 
assembly checkpoint (Figure 5.20), again suggesting a possible involvement of 
Hoxa13 in driving DNA damage and chromosome instability. In particular, from the 
Volcano Plot of obtained from the same analysis we noticed that among the most 
upregulated and most significant deregulated genes there were Aurora Kinase A 
(AurKa), Survivin (Birc5), Cyclin dependent kinase 1 (Cdk1), Cyclin dependent kinase 
inhibitor 3 (Cdkn3), Cyclin-A2 (Ccna2) and  Cell-Division-Cycle 20 (Cdc20) (Figure 
5.21).  






FIGURE 5.20. Gene expression analysis reveals commonly deregulated gene networks 
between 2 weeks livers and tumors. (A) Heatmap showing results from RNA sequencing 
performed on 2-weeks livers overexpressing Hoxa13 (n=3) and respective controls (n=3); 1 
year tumours overexpressing Hoxa13 (n=3) and respective liver controls (n=2). Hoxa13 
overexpressing samples cluster together (green). Fold-change for the represented genes is 
shown as Z-score (2,-2). (B) Pathway enrichment analysis (Reactome) performed on the 
samples from (A). Size and color of dots represent the number of genes involved in the specific 
pathway and the statistical significance (adjusted p-value), respectively.  
 





FIGURE 5.21. Volcan Plot showing the most significant DEGs genes between EGFPox and 
HOXA13ox mice.
5.4.5. Hoxa13 overexpression induced CIN signature 
Considering the results obtained with the yH2AX staining and that the vast 
majority of the genes commonly deregulated in the livers from two weeks Hoxa13ox 
mice and in the tumors belonged to the cell-cycle and the mitotic spindle-assembly 
checkpoint pathways, we decided to look for Chromosomal instability (CIN) in the 
same samples. In particular, we analyzed the levels of expression of genes 
represented in a previously described CIN signature (CIN25 and CIN70)412 and 
compared them among the two groups.  As shown in Figure 5.22, when using both 
the CIN25 (the top 25 genes most commonly found deregulated in the presence of 
CIN) and the CIN70 (all 70 genes commonly found associated with CIN), Hoxa13ox 
sample clustered together. Also, in this case, most of the genes already upregulated 
after 2 weeks were even strongly upregulated in the tumors, among which some of 
those were also the most significantly deregulated between the two groups such as 
AurkA, Ube2c and Prc1 (Figure 5.22-C).  






FIGURE 5.22. Hoxa13 overexpression induces CIN signature. (A) Heatmap showing the 
CIN25 gene signature in 2-weeks livers overexpressing Hoxa13 (n=3) and respective controls 
(n=3) plus tumors (n=3) and respective controls (n=2) of 1-year injected mice. Hoxa13 
overexpressing samples cluster together. Fold-change for the represented genes is shown as 
Z-score (2,-2). (B) Heatmap showing the CIN70 gene signature in the same samples as in A. 
Hoxa13 overexpressing samples cluster together. (C) Box Plots showing the level of 
expression (Z-score) for 8 representative genes of the CIN25 and CIN70 signatures between 









5.4.6. Chromatin Immunoprecipitation in liver cancer cell lines identified 
putative transcriptional targets of HOXA13 
To define the genome-wide DNA-binding landscape of HOXA13 in HCC and to 
identify the downstream transcriptional targets of HOXA13 which may potentially drive 
chromosomal instability and tumorigenesis, we decided to perform Chromatin 
Immunoprecipitation followed by sequencing (ChIPseq). Unfortunately, no ChIP-grade 
antibody for HOXA13 has been validated or is commercially available.  Additionally, 
few published protocols are available for performing ChIP-seq experiments on frozen 
tissue materials. Therefore, we decided to move from the in vivo system to the in vitro 
cell line model in order to optimize the experimental conditions.  To interrogate the 
DNA-binding events of HOXA13 we decided to overexpress both the native form of 
HOXA13 and the HA-tagged form of HOXA13 in two hepatic cell lines (HepG2 and 
Huh-7) such that we could perform and compare the results from the pull-down 
experiments using both a non-ChIP-grade HOXA13 antibody and a ChIP-grade HA 
antibody (Figure 5.23-A). Peaks called from the HOXA13 specific ChIP were merged 
with the ones obtained from the ChIP for HA-tagged HOXA13, resulting in a total of 
117,010 peaks for HepG2 and 40,657 peaks for Huh-7. As shown in Figure 5.23-B, 
the genome-wide distribution of the peaks was overall similar between the two cell 
lines, both in terms of features and distance from the transcriptional start site (TSS), 
but a more prominent distribution in the promoter regions in Huh-7 cells compared to 
HepG2. In general only 10% or less of the peaks annotated in the promoter regions.  
The vast majority of the peaks annotated in intronic and intergenic regions, in regions 
approximately between 10 and 100 kb distant from the TSS of the putative regulated 
genes. This is actually in accordance with other ChIPseq experiments previously 
performed for Hoxa13 on murine embryos420.   






FIGURE 5.23. Defining the genome-wide DNA-binding landscape of HOXA13 in HCC. 
(A) Schematic representation of the ChIPseq experiment. (B) Comparison of the HOXA13 
peaks distribution (%) in the genome in terms of feature (e.g. intergenic or promoter regions) 
as well as distance from TSS. Created with Biorender.com. 
 
To identify the “direct” (i.e. whose regulatory regions are directly bound by 
HOXA13) and “indirect” (i.e. not directly bound by HOXA13) targets of HOXA13, we 
decided to integrate the HOXA13 ChIP seq data from the two human liver cell lines 
with the mouse-derived RNA-seq data previously obtained. The human orthologue for 
each gene defined as differentially expressed in the mouse ‘overall’ dataset (genes 
deregulated both at 2 weeks post injection and in the tumors) was annotated with the 
nearest peak called in both HepG2 and Huh-7, along with the total number of peaks 
associated with the gene in both lines. For each gene we derived a ‘Peak score’, 
reflecting the presence of the peak in both cell lines and the number of associated 
peaks, as well as the relative distance from the TSS. The so obtained peak score was 
combined with the Z-score of the deregulated genes in order to provide us a hint into 
the putative binding targets of HOXA13 driving the phenotype in vivo. We assumed 
that the genes that had both a good peak score and were differentially expressed upon 
Hoxa13 overexpression were more prone to be real direct downstream targets of 
HOXA13. As shown in Figure 5.24, among the differentially expressed genes many 
had a peaks at least in one cell line, and among the ones with the best peak score and 
higher level of upregulation we found Aurora Kinase A (AurkA), the Cyclin dependent 





kinase 1 (Cdk1) and the Cyclin dependent kinase inhibitor 3 (Cdkn3), which we already 
previously identified as one of the most significantly deregulated genes between the 
control group and Hoxa13 overexpressing mice. We therefore speculate that Hoxa13 
may be able to drive chromosomal instability at least partially through the 
transcriptional induction of one or all those genes, an hypothesis which requires 
additional investigations.  
 
FIGURE 5.24. Combination of ChIP-seq and RNA-seq data identifies putative targets of 
HOXA13. (A) Schematic representation of the integrative analysis. (B) Log2(FC) of 
differentially expressed genes combined with their peak score from the ChIPseq.  






5.5.1. Hoxa13 acts as an oncogene by driving tumor initiation in vivo 
Liver cancer is the sixth most common cancer and the fourth cause of cancer 
death worldwide21. Mortality from this disease has significantly increased over the past 
20 years and it is predicted to still raise over the next decades421. HCC accounts for 
approximately 80% of all cases and still remains largely incurable due to low response 
rate and resistance to the available targeted therapies. Indeed, the multi-kinase 
inhibitor sorafenib, the main first-line systemic agent for HCC, only increases life 
expectancy by a few months, and nearly all patients develop resistance to it291,422. 
Several other targeted therapies have been tested for HCC, among which the 
multikinase inhibitors lenvatinib, regorafenib and cabozantinib, as well as the immune 
checkpoint inhibitors nivolumab and pembrolizumab423,424. Unfortunately, only a small 
percentage of patients respond to therapy and for these benefits last only a few 
months. These unsatisfied outcomes are mainly due to the high complexity and 
heterogeneity of HCC, for which biomarkers predictive of drug response are not yet 
available. Therefore, understanding deeper the molecular mechanisms underlying 
hepatocarcinogenesis may help finding novel and more effective therapies for HCC 
patients.   
Recently, high-throughput oncogenomic studies in combination with 
computational approaches have identified many genes deregulated along HCC 
development. However, most of these candidates are likely to be only passenger 
genes with limited implication in hepatocarcinogenesis. Therefore, in order to identify 
the real drivers oncogenes and tumor suppressor genes required for liver tumor 
initiation and progression, it is important to functionally validate them in mouse models. 
 Among the genes commonly found deregulated in HCC there are many 
embryonic or fetal liver genes. Correct embryonic development and adult liver tissue 
homeostasis requires precise patterns of cell growth and differentiation. Alteration of 
these tightly regulated patterns, such as the NOTCH425 and the Hippo signalling 
pathway426, has shown to be a key determinant of hepatocarcinogenesis. In the last 
few years, aberrant expression of the HOX gene network has also been reported in 
HCC. Dysregulated expression of Homeobox genes seem to affect several aspects of 





HCC development, including HBV427 and HCV infection427,428, liver tumor-initiating 
cells (TICs)429, EMT430,431, and immune-tolerance432. HOX genes can act as both 
positive and negative regulators in HCC progression; however, their transcriptional 
regulatory network still remains unclear. Among the HOX genes, HOXA13 has been 
reported to be the most deregulated in HCC399,407,408. More in detail, we previously 
demonstrated that HOXA13 is frequently upregulated in HCCs and its upregulation is 
associated with poor prognosis399,432. We also found that HOXA13 protein expression 
increases monotonically from normal liver to cirrhosis to HCC and correlates with poor 
differentiation363. Additionally, stable overexpression of HOXA13 in liver cancer cell 
lines resulted in increased colony formation and migration potential363. All these data 
strongly suggest a putative oncogenic role for HOXA13 in HCC development, but not 
directly prove it and also cannot discriminate between a role in tumor initiation or 
progression.  
To functionally validate the oncogenic potential of HOXA13, we successfully 
established a liver-specific Hoxa13 overexpressing mouse model using hydrodynamic 
tail vein injection coupled with a transposase system. One clear advantage of this 
system is the delivery of the target gene in a relatively low percentage of hepatocytes 
surrounded by normal/non-transfected liver cells, thus better resembling what 
happens in humans. The choice of the system is also critical considering the role of 
HOXA13 as a master regulator of embryonic development. Hydrodynamic injection is 
in fact performed in 6-to-8-week old mice, thus avoiding any possible deleterious effect 
on the mouse embryos. Through this model, we proved for the first time that Hoxa13 
overexpression per se is able to drive hepatocytes proliferation and liver tumorigenesis 
in vivo. Our results are of particular relevance since all the previous data about the 
putative oncogenic role of HOXA13 were so far obtained in liver cancer cell lines363. 
The use of liver cancer cell lines and in vitro studies has significant limitations because 
these cells are already transformed into tumor cells. Mouse models are instead critical 
to demonstrate the oncogenic potential of an aberrantly expressed gene or an altered 
signaling pathway and to illustrate how these genes contribute to tumor initiation and 
progression. By overexpressing Hoxa13 in normal murine hepatocytes we proved that 
Hoxa13 acts as an oncogene and it is able to drive tumor initiation in the liver. In 
particular, in our cohort each mouse developed several tumor nodules, all very 





heterogeneous in terms of histology, spanning from well differentiated HCC to very 
undifferentiated or ICC-like nodules. Some of the nodules also positively stained for 
the stem-like marker CK-19, usually an indicator of poor differentiation and 
aggressiveness.  Accordingly, some of the mice also developed tumor metastasis in 
the lung and in the spleen. As mentioned, HOXA13 overexpression in human 
hepatocarcinoma usually correlates with a more aggressive phenotype and poor 
prognosis, thus being in line with the phenotype we obtained in the mice. 
 Additionally, transcriptomic analysis of two-weeks mice overexpressing Hoxa13 
combined with the gene expression profiles of the tumors, revealed common pattern 
of deregulated genes. Among those genes many have been previously identified as  
key differentially expressed genes between cirrothic tissue and HCCs433,434. In 
particular, in different comprehensive bioinformatics analyses 12 hub genes were 
identified as the key genes in HCC, including TTK, NCAPG, TOP2A, CCNB1, CDK1, 
PRC1, UBE2C, CDKN3, AURKA and RACGAP1, all among the most differentially 
expressed genes  between control and Hoxa13ox mice in our cohort. Those findings 
further corroborate our hypothesis of HOXA13 overexpression having a causal role in 
liver tumor initiation and specifically suggests that the transcriptional landscape in the 
hepatocytes as re-shaped by HOXA13 dysregulation may indeed favor progression 
from cirrhotic lesion to HCC.  
5.5.2. Hoxa13 oncogenic properties are at least partially driven by the induction 
of chromosomal instability 
Another strong point of our model is the possibility to follow over-time the 
phenotype induced by Hoxa13 overexpression. In particular, with the present work we 
have shown that Hoxa13 is driving hepatocytes proliferation, DNA damage response 
and apoptosis early after its overexpression (two weeks post-injection) and that over 
time the proliferative and genotoxic phenotype were kept while the apoptotic one was 
lost. Induction of apoptosis is one of the most common regulatory mechanisms used 
by normal cells to protect them from oncogenic activation. Genotoxic stress also 
causes proliferating cells to activate the DNA damage checkpoint, to assist DNA 
damage recovery by slowing cell cycle progression or by inducing apoptosis. The 
importance of DNA damage checkpoints is highlighted by the fact that their 
dysregulation is the fundamental basis of oncogenesis435. Thus, to drive proliferation, 





cells must tolerate DNA damage and suppress the checkpoint response. Based on 
our results we hypothesize that early after hydrodynamic injection Hoxa13 strong 
overexpression induced oncogenic stress in the hepatocytes, followed by apoptosis 
and compensatory proliferation, as suggested by the fact that not all the proliferative 
hepatocytes were positively stained for Hoxa13. The hepatocytes that were able to 
escape the DNA-damage and cell-cycle checkpoints kept proliferating over time and 
accumulated more DNA damage over time. Accordingly, at four and twelve weeks post 
HTVI, hepatocytes still stained for Hoxa13, Ki67 and yH2AX, while no further signs of 
apoptosis were detectable. In our hypothesis, the cell population which was able to 
escape cell death accumulated progressive genomic instability over time thus resulting 
in additional mutations and hepatocarcinogenesis one year post-injection. Indeed, 
some oncoproteins engage multiple signal transduction pathways which can 
concomitantly activate cell proliferation and inactivate the cell-cycle checkpoints. Such 
oncoproteins may therefore be less reliant on secondary genetic or epigenetic hits to 
initiate tumorigenesis. This may be the case of HOXA13, thus explaining why its only 
overexpression was sufficient to induce liver tumor formation per se.  
Our data strongly suggest that chromosomal instability may at least partially 
explain the oncogenic properties of Hoxa13 in vivo. In particular, when looking for 
genes that were deregulated both at two weeks post HTVI and in the tumors, we 
mainly obtained pathway enrichment in cell-cycle progression, specifically in the 
mitotic cell-cycle checkpoint. Many of the genes encode for regulators of chromosome 
attachment to kinetochores and resolution of sister chromatid cohesion. In particular, 
we noticed that many of them were part of a signature usually associated with 
chromosomal instability (CIN25 and CIN70)412. When specifically checking this 
signature in our cohort we found that was associated with Hoxa13 overexpression thus 
leading to a clear clustering of the Hoxa13ox mice (both two weeks and tumors) 
compared to the controls.  
Several reports literature strongly suggest that CIN is acquired early in 
hepatocarcinogenesis436. In vitro transformation of cell lines through various genetic 
alterations that lead to CIN and sophisticated mouse modeling approaches strongly 
suggest that CIN is not simply a passenger phenotype but probably plays a causative 
role in a substantial proportion of malignancies412.  





Mitotic checkpoint overexpression, as the one induced by Hoxa13 in our model, 
results in a prolonged mitosis and an increased incidence of merotelic attachments 
and lagging chromosomes. Mitotic checkpoint overactivation is a frequent observation 
in human tumors and is sufficient to generate CIN in vivo and in vitro 437.   In vitro 
studies using agents interfering with the polymerization of microtubules, such as  
nocodazole and monastrol, together with in vivo studies overexpressing mitotic 
checkpoint genes, favour the hypothesis that tumorigenesis is a consequence of 
checkpoint over-activation437,438. Induction of chromosomal instability mediated by the 
Hippo signalling pathway through activation of Foxm1 has already been shown to be 
hepatocarcinogenic in mice412. In particular, Foxm1 has been demonstrated to 
transcriptionally activate most of the genes included in the CIN signature412 and we 
also found it among the most differentially expressed genes in our Hoxa13ox cohort.  
The association of HOXA13 and chromosomal instability have been already 
shown in previous reports. Indeed, we have previously shown that HOXA13 
hyperexpression links to HCCs of G3 group400, tumors characterized by deregulation 
of cell-cycle/nuclear export related genes, poorest prognosis and chromosomal 
instability439. In particular, HCC selection on the basis of HOXA13 overexpression 
correlates, at transcriptome level, with the upregulation of genes mostly encoding for 
cell-cycle regulators, cyclin-dependent kinases, mitotic check-point proteins and 
cytoskeletal components, with many of these genes being included in the CIN 
signature and found differentially expressed also in our mice cohort (e.g. CDKN3, 
KIF20A, MAD2L1, CCNB2, MELK).   
In agreement with previous reports, our results strongly suggest HOXA13 as a 
biomarker for CIN and initiation of HCC, although these data need to be further 
corroborating in bigger patients cohorts. 
5.5.3. The genome-wide binding landscape of HOXA13 in HCC reveals putative 
direct targets as drivers of CIN 
In order to discriminate which of the most differentially expressed genes was a 
direct target of Hoxa13, we coupled the RNAseq data obtained in vivo with the 
ChIPseq data performed in vitro. Merging of the two dataset allowed the identification 
of some putative direct targets of HOXA13 which may at least partially account for the 





chromosomal instability. Of note, we could not find annotated peaks for FOXM1 in 
both liver cancer cell lines, therefore we could not confirm that FOXM1 is a direct target 
of HOXA13.  However, based on the enrichment in expression and the annotated peak 
score, we selected AURKA, CDKN3, CDK1 and RACGAP1 as the most interesting 
putative targets. The cyclin B-CDK1 complex, the Aurora kinases and Polo-like kinase 
1 (PLK1), cooperatively regulate distinct mitotic processes440. The complex formed by 
cyclin B and CDK1 is the master regulator of mitosis and  the serine-threonine kinases 
of the Aurora family and the founding member of the Polo-like kinase (PLK) family, 
PLK1, are found in all eukaryotic lineages and cooperate with CDK1 in the control of 
mitosis and cytokinesis, being essential for proper execution of these processes441,442. 
These mitotic kinases are frequently overexpressed in cancers440,443 and are 
considered as attractive anticancer drug targets444.  
 Sixty percent (60%) of HCC cases show an increase of AURKA mRNA and 
protein levels. However, AURKA genomic amplification is detected only in 3% of HCC, 
indicating that other mechanisms are involved in AURKA activation445,446. Previous 
data support the hypothesis of AURORA A KINASE as a putative target of HOXA13. 
For instance, in pancreatic cell lines AURKA expression has been shown to be 
regulated by HOTTIP, the HOXA13 associated long-non-conding RNA446. Additionally, 
Aurora A Kinase has been shown to regulate Drosophila larval and mouse zygote 
development445–447 and RNA profiling data set generated by the Mouse ENCODE 
project448 show that Aurora A Kinase expression levels are high in placenta, testis, 
limb E14.5 and developmental liver (E14.5-E18) while almost undetectable in the adult 
liver, in accordance with the level of expression of Hoxa13 and its role in tissue 
specification. Of note,  overexpression of Aurora-A in liver has been linked to 
chromosomal instability and low incidence (3.8%) of hepatic tumor formation after a 
long latency period449. All these data strongly suggest the hypothesis of AURKA as a 
direct target of HOXA13 and one of the mediators of HOXA13 driven CIN. In support 
of this model, additional data also show a role of Aurora A in the regulation of many 
other differentially expressed genes in our Hoxa13ox cohort. For instance, it has been 
shown that Aurora-A stabilizes FOXM1 in late M phase and early G1 phase of the cell 
cycle, thus promoting cell proliferation450. Aurora A is also known to be involved in a 
CDC25B-CDK1-AURKA axis which facilitated the G2/M transition and induce cancer 





cell proliferation, promoting the growth of subcutaneous tumors and Ki67 proliferation 
index in mice451. In addition to its role in mitotic checkpoint regulation and genomic 
instability, Aurora A has also been shown to have an essential role in the pluripotency 
of stem cells and inhibition of apoptosis, through its negative regulation of p53452,453. 
This last finding also acts in favor of possible HOXA13-Aurora Kinase axis acting in 
development and being dysregulated in cancer.  
 As Aurora A, CDK1 is also a key regulator of mitosis and is conserved across all 
eukaryotes454,455. Indeed, it has been proved to be the only essential cell cycle CDK, 
as its ablation leads to the arrest of embryonic development456,457. Of note, CDK1 has 
been shown to play an essential role in development and stemness458. In embryos, 
CDK1 binds to all cyclins, resulting in the phosphorylation of the retinoblastoma protein 
pRb and the expression of genes that are regulated by E2F transcription factors456. 
Recently, CDK1 has been shown to play an essential role in the CDK1-PDK1-PI3K/Akt 
kinase signaling pathway in the regulation of self-renewal, differentiation, and somatic 
reprogramming459. Furthermore, proteomic analysis revealed an interaction between 
CDK1 and the pluripotent stem cell transcription factor SOX2 and recognize a role for 
CDK1 in regulating tumor-initiating capacity in melanoma460.  
As with Aurora kinase A, in mice also Cdk1 expression in restricted to E14.5 limbs 
and embryonic liver (E14.5-E18) while almost undetectable in the adult tissue. In liver, 
CDK1 is also reported to be overexpressed and to drive cell proliferation461 and anti-
CDK1 treatment has been proved to boost sorafenib antitumor responses in PDX 
tumor models454. Of particular relevance, loss of CDK1 in the liver confers complete 
resistance against tumorigenesis induced by activated Ras and silencing of p53457 and 
triggered apoptosis of MYC-driven mouse lymphomas and liver tumors462,463 , as well 
as human basal-like triple-negative breast cancer cells464. Few published papers also 
suggest a regulatory network between HOX genes and CDK1465,466 in cancer. All these 
data strongly support the hypothesis of CDK1 as another putative downstream target 
of HOXA13 driven tumorigenesis.  
Additional experiments need to be performed in order to validate Aurora A Kinase 
as a direct target of HOXA13 and as a mediator of its effects on the cell-cycle 
regulation in the liver. In particular, we plan to test the hypothesis in liver cancer cell 
lines overexpressing or downregulating HOXA13, evaluating Aurora A kinase 





expression and checking if the modulation of its expression or activation is able to 
revert the oncogenic potential of HOXA13 in vitro and its effect on cell cycle 
progression. Same experimental approach will be used in order to validate the other 
putative targets previously mentioned.  
5.5.4. Clinical implications of HOXA13 driven chromosomal instability 
Over 80% of solid tumors are affected by chromosomal instability467 which favors 
tumor heterogeneity,  the biggest challenge in today's cancer research. More recently, 
evidence indicates that CIN in cancer stem cells may in particular limit the success of 
targeted therapies468. Targeting CIN is therefore one key strategy in the battle against 
tumor heterogeneity and cancer therapy resistance. This is even more true for a solid 
tumor such as HCC, where tumor heterogeneity is a characteristic feature and the 
main reason for therapeutic regimens failure.  Taken together, our findings suggest a 
direct and causative role of HOXA13 in CIN and CIN-induced hepatocarcinogenesis. 
In particular, the key function played by HOX genes in embryonic developed and 
stemness, coupled with the aggressive phenotype and the huge heterogeneity 
displayed by the HCC nodules developed in our murine cohort, strongly support a 
crucial action of HOXA13 in CIN-induced tumor heterogeneity. 
One classical strategy to target CIN is to induce mitotic catastrophe through the 
use of paclitaxel and other microtubule targeting agents469. Other traditional 
chemotherapeutic agents, such as DNA-intercalating agents, are thought to work 
through CIN-inducing mechanisms since normal cells are better able to tolerate and 
repair genetic insults that cancer cells cannot469. 
The fact that cells with CIN have evolved to survive repeated rounds of mitotic 
arrests suggests that it might be preferable to inhibit the mitotic checkpoint or the 
centrosome abnormalities previously described. Targeted drug delivery or perhaps the 
hypersensitivity of tumour cells addicted to an overactive checkpoint might provide the 
therapeutic window required for drug efficacy. As mentioned, master regulators of cell-
cycle checkpoints are considered attractive anticancer drug targets and for some of 
those, inhibitors have been developed and are currently being tested in clinical 
trials444, with the majority of pre-clinical and clinical data deriving from solid tumors. 
For instance, there are currently many compounds targeting Aurora A and many of 





them, particularly alisertib, have been extensively studied in preclinical models and 
demonstrated synergy with many other targeted therapies, leading to tumour 
regression in various cancer models452,470-471. Similarly, small molecule inhibitors have 
been developed against CDK1472,473, another candidate of the HOXA13 induced 
tumorigenicity. Inhibitors of PLK1, such as rigosertib and volasertib, have also shown 
encouraging results in clinical phase II/III studies for patients with myelodysplastic 
syndromes and acute myelogenous leukaemia, respectively, and several phase III 
trials are currently ongoing. The dysregulation of many mitotic genes induced by 
Hoxa13 overexpression in murine hepatocytes suggests that HOXA13 overexpressing 
HCC patients may be suitable for these cell-cycle checkpoint inhibitors, thus opening 
new therapeutic options for a specific subgroup of patients. This is of particular 
relevance since Aurora A and other cell-cycle kinase inhibitors have so far shown low 
response in clinical trials, probably due to the absence of predictive biomarkers. We 
plan to further test our hypothesis by checking HOXA13 and CIN signature413 
expression in bigger human HCC patients cohorts public available, and by testing the 
effect of Aurora A kinase and other mitotic checkpoint inhibitors on HOXA13 
overexpressing and silenced liver cancer cell lines. Additionally, taking advantage of 
a big HCC PDX model cohort available at the Department of Biomedicine in Basel, we 
aim to test the efficacy of these drugs in HOXA13 high versus HOXA13 low PDXs474.  
5.5.5. Limitations of our study and future perspectives 
Our study is of great relevance since it has for the first time validated the tumorigenic 
properties of HOXA13 in vivo and identified it as a novel oncogene promoting tumor 
initiation in the liver. Additionally, our data further gain insight into the molecular 
mechanisms underlying cell-cycle deregulation and chromosomal instability in 
hepatocarcinogenesis, thus strengthening the already existing data in support of CIN 
as an early event in tumorigenesis. However, many limitations of our study should be 
taken into account.  
The first consideration concerns the in vivo model we choose. Although we have 
already discussed the advantages of hydrodynamic injection compared to standard 
transgenic mouse models, some limitations also apply to this technology. The first one 
pertains to the difference between human liver tumors and those generated by HTVI. 





Indeed, only a few tumor nodules usually develop in human patients while with HTVI 
all the transfected cells can potentially generate tumors. This leads to numerous tumor 
nodules throughout the mouse liver, as we have also experienced in our model. 
Additionally, the method per se accounts for a certain degree of variability. Indeed, as 
a very fast and delicate procedure, HTVI is highly dependent on the injection efficiency, 
which in the end leads to a variable spectrum of expression level of the oncogene in 
the different hit hepatocytes. However, the most important drawback of this technique 
is the context in which tumors arise. While in humans HCCs usually develop on a 
background of fibrotic or cirrhotic liver, with HTVI genes are delivered into the normal 
liver. This important aspect of hydrodynamic injection has to be taken into account 
when validating oncogenes in vivo, since it does not truly resemble the physiological 
context in which hepatocytes transformation usually takes place. This is also valid in 
our case, where we were still lucky to obtain tumors after a long latency period (one 
year post-HTVI). It would be interesting to induce cirrhosis in mice before 
hydrodynamically transfecting HOXA13 to study how it promotes tumor development 
in a fibrotic microenvironment and if this is enough to accelerate HOXA13 driven 
tumorigenesis. Connected to this point is another key aspect of this method, HTVI 
strategy is in truth highly useful to study the contribution of HOXA13 to tumor initiation, 
but not tumor progression. To investigate the role of HOXA13 in tumor progression, 
indeed, we should perform its hydrodynamic transfection in environmental (ethanol 
consumption, high-fat diet, and exposure to hepatocarcinogens) or genetic (injection 
in mice depleted of tumor-suppressor genes and co-injection with weak oncogenes) 
cancer-prone conditions. In particular, considering the role of HOXA13 in cell-cycle 
checkpoints regulation and genomic instability, we are specially interested in 
overexpress HOXA13 in TP53 mutant livers.  
Another limitation of our study pertains to the intent to merge data deriving from 
an in vivo models with data deriving from cell lines. In particular, we have coupled the 
transcriptomic analysis performed on the murine livers with the ChIP-sequencing data 
deriving from human liver cancer cell lines. Few considerations then need to be made. 
First of all, despite the huge similarities in the biology of mice and humans, we have 
always to keep in mind that when comparing two different species this may account 
for the presence or absence of certain transcriptional factors or pathways involved. 





Second of all, in our in vivo experiments we have overexpressed Hoxa13 in the context 
of normal hepatocytes, while in the ChIP experiments we have actually overexpressed 
HOXA13 in cells already transformed. Considering the re-shaping of the entire 
transcriptional machinery that usually follows cell transformation, it wouldn’t be 
unexpected if the genome-wide binding landscape of HOXA13 may highly vary 
between normal and transformed liver cells.  However, we have chosen this approach 
despite its obvious limitations because we needed first to optimize the conditions for a 
proper chromatin immunoprecipitation of HOXA13 in vitro. Additionally, it has to be 
considered that the sensitivity of the RNA sequencing might have failed in identifying 
some genes which are actually deregulated upon Hoxa13 overexpression, while the 
most differentially expressed ones do not necessarily account for the direct 
downstream effectors of Hoxa13. Despite the above-mentioned limitations, we were 
still able to identify some putative down-stream targets of HOXA13 which were 
differentially expressed in vivo and also showed peak enrichments in both human 
cancer cell lines, thus indicating that at least some targets of HOXA13 are conserved 
between the two species and between normal and transformed liver cells. In the future, 
we plan to perform ChIP directly on the fresh murine livers overexpressing Hoxa13 
and to couple this data with transcriptomic and proteomic analysis performed on the 
same derived tissues. We hope that this will help us to gain better insight into the 
genome-wide binding landscape of HOXA13 and the molecular pathways involved in 
its driven tumor-initiation.  
Last, a few additional factors should be considered in the context of the 
transcriptional role of HOXA13. It has already been described that HOXA13 binding 
events mainly occur in intergenic and intronic regions and only ~10% of the HOXA13 
binding sites are located in promoter regions475. HOXA13 binding usually induces 
substantial chromatin remodelling which affects the expression of genes located 
between 10 to 100 kB from the binding site. Therefore, more than a classical 
transcriptional factor, HOXA13 looks to act as a master regulator able to completely 
re-shape chromatin structure and most probably have huge reprogramming effects. 
Therefore, studying the DNA-binding landscape and transcription regulation mediated 
by HOXA13 cannot prescind from a deeper analysis of the histone marks and 
chromatin accessibility modification induced by its binding. More in detail, to identify 





chromatin regulatory motifs (CRMs) whose functional state depends on HOXA13 in 
the liver, we plan to also generate a genome-wide maps of histone marks H3K27ac 
and H3K27me3 in the HOXA13 overexpressing and knock-out liver cells, as already 
published in vivo475, as well as perform an Assay for Transposase Accessible 
Chromatin (ATAC) sequencing. To contextualize the association between HOXA13 
binding and its differential regulatory activity, we will plot the distribution of CRMs 
relative to the nearest HOXA13 peak as previously described475. Moreover, we plan 
to also perform global proteome analysis on both murine tissues and cell lines in order 
to identify the protein interactors of HOXA13 and therefore its main transcriptional co-
factors.  
In conclusion, our work shows for the first time that HOXA13 overexpression alone 
is able to induce hepatocyte proliferation, DNA damage and tumor liver development 
in mice. Our results suggest a role for HOXA13 as a novel putative oncogenic driver 
in hepatocarcinogenesis and strongly suggest that its oncogenic properties are least 
partially mediated by deregulation of key mitotic checkpoints and induction of 
chromosomal instability. 
  





6. General Conclusions 
 
Dysregulation of transcription factors represents a typical hallmark of cancer,  as 
transcription factors account for about 20% of all oncogenes identified so far476. 
Besides house-keeping transcription factors, some are spatially, temporally and 
sequentially expressed in tissues during development, cell renewal or differentiation 
processes. Unfortunately,  transcription factors are usually considered “undruggable” 
candidates because of their nuclear localization and absence of a well-defined drug 
binding site. One of the challenges of precision oncology is then to define how these 
factors induce neoplastic changes as well as to determine their regulatory networks in 
order to find alternative drug targets.  
 
Transcription factors acting as master regulators of embryonic development play 
a critical role in cancer, as their dysregulation usually associate with a more aggressive 
phenotype and unfavorable outcome. Homeodomain transcription factors and GATA 
zinc finger transcription factors both control cell fate decisions during embryonic and 
adult development and are found dysregulated in several human cancers, among 
which breast and liver cancer. GATA3, in particular, is an embryonic master regulator 
of the mammary gland often found mutated in estrogen receptor-positive breast 
cancers. HOX genes, instead, maintain tissue homeostasis by preserving the spatio-
temporal coordinates established during embryonic growth and HOXA13, specifically, 
has been reported to be the most deregulated HOX gene in HCC.  
With the present doctoral work we explored the role and therapeutic implications 
of the deregulation of GATA3 and HOXA13 in breast and liver cancer, respectively. 
More in detail, in the first project we have defined a synthetic lethal interaction of 
GATA3 loss of function in estrogen positive breast cancer while with the second project 
we have proved the liver-oncogenicity of HOXA13 in vivo as well as its implication in 
chromosomal instability. The relevance of our findings specifically relates to the 
association of both GATA3 loss or HOXA13 overexpression with poor prognosis and 
occurrence of resistance to therapy, respectively in estrogen positive breast cancer or 
HCC. Additionally, the existence of clinically available drugs targeting MDM2, 
identified by us as the synthetic lethal partner of GATA3, or drugs directed against 





Aurora A Kinase, identified as a putative downstream effector of HOXA13 in HCC, 
makes our findings more relevant thus suggesting an alternative therapeutic option for 
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• Identification and validation of new synthetic lethal interactions 
in cancer to extend precision oncology in patients with specific 
mutations. Co-author of a patent application 
• In vivo study (transgenic mouse models) of new molecular 
mechanisms of hepatocarcinogenesis 
Internship - M.Sc. graduate    Mar 2013 – Oct 2015 
National Council of Research (CNR), Naples (IT) 
Study of the role of autophagy in epithelial cancer cell lines.  
EDUCATION  
Ph.D. in Biomedical research  6/6 summa cum laude Mar 2013 – Oct 2015 
  University of Basel (CH), 2019 
M.Sc. in Biotechnology 110/ 110 summa cum laude 4Mar 2013 – Oct 2015 
University of Naples Federico II (IT), 2014  
B.Sc. in Biotechnology 110/110 magna cum laude  2013 – Oct 2015 






Good clinical practice for 
investigators and study team 
(IHC-GCP) - Swiss TPH 
 
Laboratory Animal Science 
Certificate - LTK module 1 - 
ETH Zurich 
 
COURSES & AWARDS 
• Summa cum laude doctoral 
dissertation (2019) 
• Selected speaker for the 4th 
Joint Annual Meeting of the 
Swiss and Austrian Societies 
of Pathology (2019) 
• Selected female Ph.D. 
candidate for the 
Antelope@Novartis career 
program (2018) 
• Dean’s award for academic 
achievements (M.Sc., 2014) 
• Winner of university 





Director Regional Partnership – NIBR 
(mentor for the Antelope@Novartis) 
michael.kangas@novartis.com 
  
Prof. Dr. Mathias Heikenwälder  
Division Head Chronic inflammation and 
Cancer – DKFZ (Ph.D. supervisor)  
m.heikenwaelder@dkfz-heidelberg.de 
 
Dr. med. Lana Fourie  
Oberärtzin Abdominal Surgery – 
University Hospital Basel  
lana.fourie@clarunis.ch 
 
Dr. Mairene Coto-Llerena  





• Design of research plans at the interface of basic and 
clinical science  
• Collection, analysis and interpretation of experimental 
datasets as well as clinic-pathological information (multi-omics 
data, in vitro and ex-vivo cytotoxicity assays, fluorescence-
activated cell sorting, microscopy, immuno-staining) 
• Ability to work in a multi-disciplinary team (molecular 
biologists, bioinformaticians, pathologists, clinicians, patent 
attorneys)  
• Ability to effectively transfer knowledge (teaching to B.sc. 
undergraduates, training of clinicians, presenting data at 
conferences) 
• Creative with robust data visualization skills 
• Strong oral and written communication  
• Excellent organizational and multi-tasking skills 
• Attention to details and quality oriented 
• Strength in problem-solving and decision-making 
SELECTED PUBLICATIONS 
• Bianco G et al. GATA3 and MDM2 are synthetic lethal in oestrogen-
receptor positive breast cancer (In submission). 
       https://www.biorxiv.org/content/10.1101/2020.05.18.101998v1 
• Taha-Melitz S, Bianco G* et al. Adenylosuccinate lyase is oncogenic in 
colorectal cancer and predicts response to 6-mercaptopurine. 
Theranostics 2020 (under revision). *joint first author 
• Bianco G et al. Hoxa13 drives hepatocytes proliferation and liver 
tumorigenesis in mice. AACR 2019 (Manuscript in preparation).  
• https://cancerres.aacrjournals.org/content/79/13_Supplement/4612  
• Srivatsa S, Montazeri H, Bianco G,* et al. Discovery of synthetic lethal 
interactions from large-scale pan-cancer perturbation screens. Nature 
Communication 2019 (under revision). *joint first author 
• https://www.biorxiv.org/content/10.1101/810374v1  
• Montazeri H, Coto-Llerena M, Bianco G,* et al. APSiC: Analysis of 
perturbation screens for the identification of novel cancer genes. 
Nucleic Acids Research 2019 (under revision). *joint first author 
• https://www.biorxiv.org/content/10.1101/807248v1  
• Lanzafame M, Bianco G* et al. The role of long non-coding RNAs in 
hepatocarcinogenesis. International Journal of Molecular Sciences 
(MDPI) 2018.  *joint first author 
• Lorentz A, … Bianco G. et al. Single cell polarity in liquid phase 
facilitates tumor metastasis. Nature Communication 2018.  
• Conte A, … Bianco G. et al. High mobility group A1 protein modulates 
autophagy in cancer cells. Cell Death and Differentiation 2017 
PATENT APPLICATIONS 
“MDM2 inhibitor response Prediction Method and Use of MDM2 
inhibitors.” (applicants: University of Basel and ETH Zürich; name of 
the inventors: G.B, S.S., H.M., N.B., C.K.Y.N. and S.P. application 
number: EP19216550.4) 
 
